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Main points  
• Untimely upregulation of GPR17 impairs oligodendrocyte maturation and myelination 
• Mdm2 regulates GPR17 responses at the cell membrane by intertwining mTOR with 
GRK2 
• Unprecedented role for Mdm2 ubiquitin ligase in oligodendrogenesis and myelination 
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Abstract  
During oligodendrocyte precursor cell (OPC) differentiation, defective control of the 
membrane receptor GPR17 has been suggested to block cell maturation and impair re-
myelination under de-myelinating conditions. 
After the immature oligodendrocyte stage, to enable cells to complete maturation, 
GPR17 is physiologically down-regulated via phosphorylation/desensitization by G protein-
coupled Receptor Kinases (GRKs); conversely, GRKs are regulated by the “mammalian 
target of rapamycin” mTOR. However, how GRKs and mTOR are connected to each other in 
modulating GPR17 function and oligodendrogenesis has remained elusive. 
Here we show, for the first time, a role for Murine double minute 2 (Mdm2), a ligase 
previously involved in ubiquitination/degradation of the onco-suppressor p53 protein. In 
maturing OPCs, both rapamycin and Nutlin-3, a small molecule inhibitor of Mdm2-p53 
interactions, increased GRK2 sequestration by Mdm2, leading to impaired GPR17 down-
regulation and OPC maturation block. Thus, Mdm2 intertwines mTOR with GRK2 in 
regulating GPR17 and oligodendrogenesis and represents a novel actor in myelination. 
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Introduction  
Remyelination after central nervous system (CNS) insults is needed to re-establish nerve 
conduction and prevent axonal loss. Spontaneous remyelination based on recruitment and 
proliferation of oligodendrocyte precursor cells (OPCs) is defective in diseases such as 
multiple sclerosis, mainly due to an OPC differentiation block (Franklin and Ffrench-
Constant 2008; Kuhlmann et al., 2008). Identifying the mechanisms involved in defective 
OPC differentiation is important for developing new remyelinating strategies.  
The P2Y-like GPR17 receptor responding to uracil-nucleotides and cysteinyl-
leukotrienes (cysLTs), two families of mediators involved in CNS repair (Ciana et al., 2006), 
is a key regulator of OPC maturation (Chen et al., 2009; Coppi et al., 2013; Lecca et al., 
2008). GPR17 is expressed by a subpopulation of early OPCs and it is needed to start 
differentiation; however, GPR17 is turned down before cells reach maturation (Fumagalli et 
al., 2011). GPR17 responses are regulated by its endogenous ligands; by binding to the 
receptor, ligands first induce OPCs to undergo differentiation and then switch GPR17 off, 
inducing its desensitization/down-regulation and cytoplasmic internalization. These latter 
events involve specific isoforms of G-protein-coupled receptor kinases (GRKs), either GRK2 
or GRK5, depending on the class of ligand bound to the receptor (Daniele et al., 2014). 
Alterations of GPR17 activation and physiological silencing at specific OPC differentiation 
phases may lead to myelination defects and be even at the basis of demyelinating diseases. 
In various in vivo neurodegenerative models characterized by myelin loss (stroke, 
trauma, demyelination and experimental autoimmune encephalomyelitis), GPR17 was 
abnormally up-regulated in OPCs around lesion sites (Boda et al., 2011; Chen et al., 2009; 
Lecca et al., 2008). Accordingly, we recently reported that decreased GRKs levels resulting 
in defective GPR17 desensitization markedly reduce OPC maturation (Daniele et al., 2014). 
Of interest, altered GRKs expression/activity has been implicated in human inflammatory 
and demyelinating diseases (Gurevich et al., 2012; Vroon et al., 2005). 
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GRKs alterations may, in turn, depend on mTOR (the “mammalian target of 
rapamycin”), a serine/threonine protein-kinase inhibited by the immunosuppressive agent 
rapamycin (RAPA). mTOR is central to cell growth, differentiation and survival and has been 
implicated in oligodendrocyte (OL) development and myelination (Tyler et al., 2009). 
Interestingly, a recent proteomic analysis highlighted increased levels of GPR17 in RAPA–
treated OPCs, suggesting this receptor as a putative target for mTOR (Tyler et al., 2011). 
Despite this initial evidence, the relationships between mTOR, GRKs, GPR17, its interacting 
proteins and OL maturation have remained elusive. 
Here, we demonstrate that, in rat primary OPCs, inhibition of mTOR by RAPA reduces 
GRK2 levels and prevents GPR17 down-regulation/desensitization, strongly inhibiting OPC 
maturation. We also prove, for the first time, that Mdm2 (Murine double minute-2), a ligase 
previously involved in the ubiquitination/degradation of the onco-suppressive p53 protein 
and in tumor progression (Ashcroft and Vousden 1999) specifically controls OPC maturation 
by intertwining mTOR with GRK2.  
 
Materials and Methods 
Oligodendrocyte precursor cell cultures 
Primary OPCs were isolated from mixed glial cultures prepared from postnatal day 2 
Sprague–Dawley rat cortex by shaking cells on an orbital shaker at 200 rpm, as previously 
described (Fumagalli et al., 2011). OPCs were then collected and separated from microglia 
by incubation for 1h on an uncoated Petri dish. Purified OPCs were seeded onto poly-D,L-
ornithine-coated glass coverlisps or plates (50 µg/ml, Sigma-Aldrich, Milan, Italy) to a 
specific density according to the planned experiments (see below), in Neurobasal (Life 
Technologies, Monza, Italy) with 2% B27 (Life Technologies), 2 mM L-glutamine 
(EuroClone), 10 ng/ml human platelet-derived growth factor BB (Sigma-Aldrich), and 10 
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ng/ml human basic fibroblast growth factor (Space Import Export, Milan, Italy), to promote 
proliferation. After 2 day, cells were switched to a Neurobasal medium lacking growth 
factors to allow differentiation. In some experiments triiodothyronine T3 (Sigma Aldrich) 
was also added to a final concentration of 10 ng/ml.  
 
In vitro pharmacological treatments 
According to the planned experiments, cells were plated in 13 mm glass coverslip or in 60 
mm diameter petri dish (20,000 cells/coverslip or 100,000 cells/dish) maintained for 2 days in 
Neurobasal supplemented with B27 and proliferative factors (PDGF-BB and bFGF) and then, 
after one day in differentiating medium, cells were treated with either rapamycin (15 nM) 
(Sigma-Aldrich) or with Nutlin-3 (NUT, 1 µM) (Sigma Aldrich). Cells were fixed for 
immunocytochemistry (ICC) or lysed for WB analysis at day 4 or 6 (see also figure legends 
for details).  
 
Generation of pGPR17-EGFP-N1 plasmid and OPC transfection  
The coding sequence of the human GPR17 receptor was subcloned from a previously 
generated pcDNA3.1 vector (Life Technologies), using specific primers containing the 
restriction cassette for XhoI and BamHI (fw: 5’-gttttttctcgagatgaatggccttgaagtggc; rv: 5’-
ggtggatccgacagctctgacttggcactca). The product was then inserted upstream to the EGFP 
sequence in a pEGFP-N1 expression vector (Clontech). For GPR17 over-expression in OPCs, 
cells were seeded on 13 mm poly-D,L-ornithine-coated coverslips (2 x 10
4
 cells/well) in 
Neurobasal supplemented with B27 and proliferative factors (PDGF-BB and bFGF). 
Differentiation was then, induced by removing proliferative factors and at day 4, cells were 
transfected with the fluorescent plasmid pGPR17-EGFP, in parallel to the corresponding 
fluorescent empty vector, using the transfection reagent NeuroFECT
TM
 (Genlantis, San 
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Diego, CA, USA) according to manufacturer's protocol. After transfection, cells were 
maintained in differentiating medium supplemented with T3 for additional 48-72 hours and 
fixed for ICC. 
 
OPCs electroporation with a GRK2 plasmid 
GRK2 overexpression was obtained by electroporating OPCs with the Amaxa Rat 
Oligodendrocyte Nucleofection Kit (Lonza, Milan, Italy) according to the manufacture’ 
instructions. In detail, OPCs were electroporated with 1 µg either of GRK2 plasmid 
(Origene) or the corresponding empty vector (OriGene, Maryland, USA) with the O-017 
program. After electroporation, cells were rapidly seeded on 13 mm poly-D,L-ornithine-
coated coverslips (5 x 10
4
 cells/well) in Neurobasal supplemented with B27 and proliferative 
factors (PDGF-BB and bFGF) and maintained in this medium. In parallel, electroporated 
OPCs were also seeded on 60 mm poly-D,L-ornithine-coated dish in order to check 
transfection efficiency by western-blot analysis. After 30 hours, electroporated OPCs were 
subjected to the cAMP assay (see below)  
 
Immunocytochemistry 
Both primary OPCs and OPC-DRG co-cultures were fixed at room temperature with 4% 
paraformaldehyde (Sigma-Aldrich) in 0.1 M PBS (Euroclone) containing 0.12 M sucrose 
(Sigma-Aldrich). Labelling was performed incubating cells overnight at 4°C with the 
following primary antibodies in Goat Serum Dilution Buffer (GSDB; 450 mM NaCl, 20 mM 
sodium phosphate buffer, pH 7.4, 15% goat serum, 0.3% Triton X-100): rat anti-MBP (1:200; 
Millipore, Milan, Italy), rabbit anti-GPR17 (1:100; Cayman, Michigan, USA), mouse anti-
SMI 31 and mouse anti SMI 32 (1:500; Cell Signaling, Beverly, MA, USA). Cells were then 
incubated for 1h at RT with the secondary goat anti-rat, goat anti-rabbit or goat anti-mouse 
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antibody conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:600 in GSDB; Molecular 
Probes, Life Technologies). Nuclei were labelled Hoechst-33258 (1:10,000, Molecular 
Probes, Life Technologies). Coverslips were finally mounted with a fluorescent mounting 
medium (Dako, Milan, Italy) and analysed under a fluorescence or confocal microscope 
(LSM510 META, Zeiss). For cell count, 10 or 20 fields were acquired at 20X magnification 
(at least 3 coverslips for each experimental condition) under an inverted fluorescence 
microscope (200M; Zeiss) connected to a PC computer equipped with the Axiovision 
software (Zeiss). Images were collected and cells scored and counted using the ImageJ 
software.  
 
Subcellular localization of Mdm2 
Primary OPCs (stage 3) were treated with medium alone (CTRL) or 15 nM RAPA for 30 
min. At the end of treatments, cells were collected and suspended in 5 mM Tris-EDTA (pH 
7.4) and nuclear cell fractions were isolated by centrifugation at 1000 x g for 15 min at 4°C. 
Mdm2 levels were detected in both cytoplasmic and nuclear fractions by immunoblotting 
using an anti-Mdm2 antibody (Santa Cruz Biotechnology, sc-812; 1:100). GAPDH (Sigma 
Aldrich, G9545, 1:5000) and hystone H3 (Santa Cruz Biotechnology, sc-8654; 1:100) were 
analysed from the same samples as loading controls for the cytosolic and nuclear fraction, 
respectively. 
 
Western blot analysis  
Cell lysates were prepared and analysed by WB as previously described (Coppi et al., 2013). 
Briefly, cells were lysed in lysis buffer (20 mM Tris pH 7.2, 0.5% deoxycholate, 1% Triton, 
0.1% SDS, 150 mM NaCl, 1 mM EDTA and 1% proteases inhibitors, Sigma-Aldrich) and, 
then, approximately 25-30 µg aliquots from each protein sample were loaded on 12% 
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sodium-dodecylsulphate polyacrylamide gels (for MBP and CNPase) or on 8.5% sodium-
dodecylsulphate polyacrylamide gels (for GPR17, NG2, GRK2 and GRK5), and blotted onto 
nitrocellulose membranes (MBP and CNPase) or PVDF membranes (GPR17, GRK2, GRK5 
and NG2) (Bio-Rad Laboratories, Segrate, Milan, Italy). Membranes were saturated with 
10% non-fat dry milk in Tris-buffered saline (TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 
1 h at room temperature and incubated overnight at 4°C with the following primary 
antibodies diluted in 5% non-fat dry milk in TBS: rabbit anti-GPR17 (1:1000, home-made 
antibody), rat anti-MBP (1:500), rabbit anti-CNPase (1:250; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), rabbit anti-GRK2 (sc-562, 1:200; Santa Cruz Biotechnology) and rabbit 
anti-GRK5 (sc-565, 1:200; Santa Cruz Biotechnology), rabbit anti-phospho mTOR (Ser2448) 
(1:500; Cell Signaling, Danvers, MA, USA), mouse anti-mTOR (1:1000; Cell Signaling). 
The following day, membranes were washed in TBS-T (TBS plus 0.1% Tween20® Sigma 
Aldrich), incubated for 1 h with goat anti-rabbit or goat anti-mouse or goat anti-rat secondary 
antibodies conjugated to horseradish peroxidase (1:4000, 1:2000 and 1:2000 in 5% non-fat 
dry milk in TBS respectively; Sigma-Aldrich). Detection of proteins was performed by 
enhanced chemiluminescence (ECL, Thermo Scientific, Rodano, Milan, Italy) and 
autoradiography. Non-specific reactions were evaluated in the presence of the secondary 
antibodies alone. Densitometric analysis of the protein bands was performed with ImageJ 
software. Band intensities were measured as integrated density volumes (IDV) and expressed 
as % of control lane values for comparisons between treatment groups. α-Tubulin (1:1500; 
Sigma Aldrich) or α-actin (1:5000; Sigma Aldrich) expression was analysed from the same 
sample as an internal control and it was used for data normalization. 
 
Measurement of cyclic AMP levels 
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For OPCs, cells were plated in 24 well-plates and after 6 days in culture in differentiation 
medium without T3, functional responsiveness of GPR17 was assessed as described, (Daniele 
et al., 2014; Fumagalli et al., 2011) using 500 nM UDP-glucose or 5 nM LTD4, as stimuli. 
For desensitisation experiments, OPCs were pre-treated with UDP-glucose (5 µM) or LTD4 
(50 nM) for different times (5-120 min), in the absence (control cells) or in the presence of 15 
nM rapamycin or 10 µM Nutlin-3. Then, cells were washed with 400 µl of saline and 
incubated at 37°C for 15 min with 0.4 ml of non-complete Neurobasal in the presence of the 
phosphodiesterase inhibitor, Ro20-1724 (20 µM) and stimulated with agonists (500 nM 
UDP-glucose or 5 nM LTD4), in the presence of 10 µM Forskolin (FK). Intracellular cAMP 
levels were measured using a competitive protein binding method, as previously reported 
(Daniele et al., 2014).  
 
ELISA assay for the detection of GPR17-GRK or Mdm2-GRK immunocomplexes 
OPCs were treated with medium alone (basal), or UDP-glucose (5µM) or with LTD4 (50 
nM), respectively for 30 min. In some experiments, cells were pre-incubated for 15 min with 
15 nM rapamycin or 10 µM Nutlin-3. Then, cells were washed twice in ice-cold phosphate-
buffered saline, collected by centrifugation, and resuspended in Lysis buffer (20 mM Tris 
HCl, 137 mM NaCl, 10% glycerol, 1% NONIDET40, 2 mM EDTA, pH 8), containing 1% of 
the Protease inhibitor Cocktail (Sigma Aldrich, Milan, Italy). Optimal composition of lysis 
buffer, as well as reaction conditions, were determined in preliminary experiments. Levels of 
GPR17-GRK or Mdm2-GRK immunocomplexes in OPC lysates, obtained as above 
described, were quantified using a validated ELISA method (Zappelli et al., 2014). 96-wells 
were pre-coated with a mouse full-length anti-Mdm2 antibody (sc-965, Santa Cruz 
Biotechnology, 1:50 in 0.05% Poly-L-Ornithine) or with an anti-N terminus GPR17 antibody 
(sc-74792, Santa Cruz Biotechnology, 1:50 in 0.05% Poly-L-Ornithine) overnight at room 
Page 11 of 85
John Wiley & Sons, Inc.
GLIA
 11
temperature. After three washes of 5 minutes with 100 µl of PBS/Tween 0.1%, cell lysates 
(50 µg in a final volume of 100 µl) were transferred to the pre-coated wells for 120 min with 
a plastic cover or film and kept under constant agitation. Three quick washes were performed 
with PBS/Tween 0.1% to remove unbound protein, and each well was incubated for 15 min 
with 1% bovine serum albumin (BSA, Sigma) to block non-specific sites. Then, wells were 
incubated for 120 min at room temperature with the specific primary antibodies: anti-GRK2 
(Santa Cruz Biotechnology, sc-562; 1:400); anti-GRK5 (Santa Cruz Biotechnology, sc-565; 
1:400). Wells were washed and incubated for 1 h with a secondary HRP-conjugate antibody 
(diluted in 5% milk), and washed again. The TMB substrate kit (Thermo Fisher Scientific) 
allowed a colorimetric quantification of the complex of GRKs with GPR17 or Mdm2. Blanks 
were obtained processing cell lysates in the absence of the primary antibodies. To avoid cross 
interactions between the different antibodies, the chosen primary antibody was always from a 
different species with respect to the antibody used for well pre-coating. Absorbance’s values 
at 450 nm were measured, background subtracted and bar graphs were generated using Graph 
Pad Prism 4 software (GraphPad Software Inc., San Diego, CA), from which the percentage 
of association between the two analysed proteins, compared to basal value, were derived. 
 
In vivo rapamycin injections. 
C57BL6/J mice were injected daily with either vehicle or rapamycin intraperitoneally at 10 
mg/kg body weight (rapamycin was diluted in the vehicle solution from a stock of 20 mg/mL 
in 100% ethanol immediately before the injection to a final concentration of 0.8 mg/mL PBS, 
5% polyethylene glycol-1000, 5% Tween 80, and 4% ethanol) starting at postnatal day (P) 
16. On P21, mice were sacrificed, brains were extracted and rapidly frozen at -80°C. 
Membrane protein extracts were obtained by tissue homogenization in lysis buffer (20 mM 
Tris pH 7.2, 0.5% deoxycholate, 1% Triton, 0.1% SDS, 150 mM NaCl, 1 mM EDTA and 1% 
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proteases inhibitors, Sigma-Aldrich). The homogenate was centrifuged at 1000g for 10 min at 
4°C in order to eliminate nuclei. The protein concentration was estimated using the Bio-Rad 
Protein Assay (Bio-Rad Laboratories s.r.l., Segrate, Italy). Western blot analysis was 
performed as described below. 
 
Statistical analysis 
All results were expressed as mean ± S.E. Statistical analysis was done with non-linear 
multipurpose curve-fitting Graph-Pad Prism program (Graph-Pad). The statistical test used 
was chosen according to the type of experiment performed and was indicated in the legend of 
the figure. Three degrees of significance were considered: P<0.05 (*), P< 0.01 (**), P < 
0.001 (***). 
 
Results 
Involvement of mTOR in GPR17 regulation during OPC differentiation 
Cultured OPCs are known to undergo different subsequent stages of differentiation 
(stages 1-5) when maintained for up to 6 days in vitro (DIV6) when they reach terminal 
maturation (stage 5 in Figure 1A). Initial data from a proteomic analysis had shown that 
RAPA increases GPR17 levels in parallel to a reduction of OPC maturation, highlighting 
GPR17 as a potential target for mTOR and suggesting that receptor silencing is required for 
OPC terminal maturation (Ceruti et al., 2011; Fumagalli et al., 2011; Lecca et al., 2008). To 
get more insights in mTOR regulation of GPR17 and on its effects on OPC maturation, as a 
first step, we performed a detailed immunocytochemical and western blot (WB) analysis of 
GPR17 in OPCs treated with RAPA from DIV1 and analysed at either DIV4 (Supplementary 
Figure S1A) or DIV6 (Figure 1B). At DIV6 (stage 5), RAPA markedly reduced the number 
of terminal MBP
+
 OLs and concomitantly increased the number of GPR17
+
 cells (Figure 1B). 
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No changes in total cell number were detected (CTRL: 527.4 ± 73.64; RAPA: 412.6 ± 55.59, 
Hoechst 33258 staining). WB analysis confirmed a significant GPR17 enhancement in 
parallel with reduced mature myelin proteins (CNPase and MBP) (Figure 1C). As shown in 
Supplementary Figure S1A, in RAPA-treated cells, an increase (+38.7%) of GPR17 
compared to CTRL was already detected at DIV4 (stage 4), together with reductions of 
CNPase and MBP. Conversely, RAPA had no effect on GPR17 at DIV3 (data not shown). To 
confirm that the effects of RAPA on OPC maturation indeed result in impairments of 
myelination, RAPA-treated cultures also showed a reduction of MBP
+
 segments extending 
along neurofilament (NF)-positive axons in neuronal/OPC co-cultures (Supplementary Figure 
S1B). To univocally endorse that GPR17 down-regulation is needed for OPC terminal 
maturation, we then transfected OPCs with a fluorescence reporter plasmid for GPR17 over-
expression (GPR17-EGFP). After 3 days, the majority of control OPCs incorporating the 
empty plasmid underwent maturation, as demonstrated by CNPase expression and large 
cytoplasmic areas with many branched processes (Figure 1D). Conversely, most OPCs 
incorporating the vector for GPR17 over-expression kept an immature morphology and 
showed reduced expression of both CNPase (Figure 1D) and MBP (data not shown). Thus, 
interference with GPR17 down-regulation resulting in permanently elevated GPR17 levels 
markedly impairs OPC differentiation.  
 
GRK2 plays a key role in mTOR regulation of GPR17 function and OL maturation 
In other cells, mTOR regulates the expression/function of membrane GPCRs by 
modulating GRKs (Cobelens et al., 2007). We previously showed that, in OPCs, GRKs are 
involved in GPR17 desensitization/internalization induced by prolonged exposure to its 
agonists, and that, depending on the type of ligand (either LTD4 or UDP-glucose), different 
GRKs (namely, GRK2 or GRK5) are preferentially recruited to regulate GPR17 functional 
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response (Daniele et al., 2014). 
To establish a functional relationship between mTOR and GRK in OPCs, we analysed the 
expression profile of these GRK isoforms at DIV4 and DIV6 in control and RAPA-treated 
cells. RAPA significant decreased GRK2 levels (Figure 2A), whereas no changes in GRK5 
were observed (Supplementary Figure S3A). Then, based on previous data showing that 
GPR17 associates to GRK2 to a higher extent after LTD4 compared to UDP-glucose (Daniele 
et al., 2014) (see also Figure 2B), we measured GPR17-GRK2 association in OPCs in 
absence or presence of RAPA, and after either LTD4 or UDP-glucose exposure. Consistent 
with data in Figure 2A, association of GPR17 to GRK2 was significantly decreased by 
RAPA, particularly when LTD4 was used to activate GPR17 (Figure 2B). GPR17 is coupled 
to Gi and its activation by agonists consequently results in marked inhibition of intracellular 
levels of cAMP (Fumagalli et al., 2011). Accordingly, in OPCs, LTD4 potently reduces the 
increases of cAMP levels induced by the cyclase activator FK (Figure 2C). This Gi mediated 
effect was progressively lost in cells exposed to the agonist for prolonged time periods, 
suggesting receptor desensitization (white columns in Figure 2C). RAPA markedly prevented 
LTD4 induced receptor desensitization despite an initial challenge with this agonist (black 
columns in Figure 2C), likely due to a decrease in GRK2 levels. In contrast, UDP-glucose, 
which activates the GRK5-dependent pathway (Daniele et al., 2014) still induced GPR17 
desensitization with kinetics similar to control OPCs (Supplementary Figure S3B). These 
results suggest that mTOR regulates GRK2 which, in turn, mediates LTD4-induced GPR17 
desensitization. To further confirm this hypothesis and unequivocally relate RAPA-induced 
decrease in GRK2 levels with loss of GPR17 desensitization, we performed “rescue 
experiments” by over-expressing GRK2 in OPCs. Electroporation of cells with a GRK2 
plasmid indeed resulted in a marked increase of GRK2 protein levels compared to the 
corresponding empty vector, as shown by western blot analysis (Fig. 2D). To make sure that 
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electroporation had no effects on GPR17 desensitization kinetics, we analyzed LTD4-
mediated loss of GPR17 function in cells electroporated with the corresponding empty 
vector. In a similar way to standard controls (Fig. 2C), pre-exposure of electroporated OPCs 
to LTD4 gradually desensitized GPR17, and, as expected, this effect was prevented by 
inhibiting mTOR with rapamycin (Supplementary Figure S2). On the contrary, in OPCs 
electroporated with the GRK2 plasmid, RAPA was no longer able to prevent LTD4-induced 
GPR17 desensitization (black columns compared to white columns in Fig. 2D). Globally, 
these results confirm that: (i) GRK2 is very important for LTD4-induced GPR17 
desensitization; (ii) mTOR normally controls GRK2 activation and GPR17 desensitization; 
(iii) inhibition of mTOR by RAPA results in prevention of GPR17 desensitization, but this 
effect is surmounted by GRK2 overexpression; (iv) GRK2 is downstream of mTOR in the 
pathway of GPR17 desensitization. 
 
 
The ubiquitin ligase Mdm2 mediates the interaction between GRK2 and mTOR 
To gain insights into mTOR-mediated mechanisms governing GRK2 levels/activity in 
OPCs, we analysed the involvement of the ubiquitin ligase Mdm2. This ligase normally acts 
as a negative regulator of the onco-suppressor p53 protein, but has also been reported to 
regulate membrane GPCRs by promoting the degradation of GRK2 in cells other than OPC 
(Freedman et al., 1999; Salcedo et al., 2006; Thut et al., 1997). On this basis, we quantified 
Mdm2-association to either GRK2 or GRK5 after mTOR inhibition. RAPA significantly 
enhanced Mdm2 association to GRK2 with no changes in Mdm2-GRK5 complexes, 
confirming that, in OPCs, Mdm2 is selective for GRK2 (Figure 3A and Supplementary 
Figure S5). These data are consistent with decreased GRK2 (Figure 2A) and unaltered GRK5 
levels in RAPA-treated OPC lysates (Supplementary Figure S3A). To more directly establish 
a functional link between Mdm2 and GRK2, we took advantage of Nutlin-3, a small-
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molecule inhibitor of Mdm2-p53 interactions (Arva et al., 2008), thus making Mdm2 more 
available for association to GRK2. Nutlin-3 (NUT) markedly enhanced Mdm2-GRK2 
association, with negligible effects on the formation of Mdm2-GRK5 complexes (Figure 3B 
and Supplementary Figure S5). Sequestration of GRK2 by Mdm2 indeed resulted in a 
marked reduction of GRK2 levels (Figure 3C), suggesting that Mdm2 drives the 
ubiquitination/degradation of this kinase. A parallel increase of GPR17 together with 
decreased CNPase levels was also detected after Nutlin-3 (Figure 3D). In line with these data, 
Nutlin-3 markedly reduced the association of GRK2 to GPR17 after OPC exposure to GPR17 
agonists, with a more marked effect after LTD4 (Figure 3E). Globally, these data suggest that, 
in OPCs, disruption of Mdm2-p53 interaction favours the association of Mdm2 to GRK2 and 
its subsequent degradation, thus impairing GRK2 interaction with GPR17 (Figure 3E).  
 
mTOR regulates the equilibrium between Mdm2-p53 and Mdm2-GRK2 complexes  
The above data suggest that mTOR signaling would shift the equilibrium from Mdm2-p53 
association to Mdm2-GRK2 association, thereby allowing GRK2 to mediate GPR17 
desensitization and OPC maturation. To substantiate this hypothesis, we directly assessed the 
association of Mdm2 to p53 upon RAPA treatment. As shown in Fig. S4, pre-treatment of 
OPCs with either RAPA or Nutlin-3 for 30 min reduced the association between Mdm2 and 
p53. Since in other cells (e.g MCF-7 cells) mTOR dependent phosphorylation of Mdm2 
stimulates its translocation from the cytoplasm to the nucleus (Mayo et al., 2001; Feng et al., 
2004; Salcedo et al., 2006), where it then associates to p53, we reasoned that mTOR 
inhibition by RAPA could result in reduced levels of nuclear Mdm2 and in elevated 
expression of cytosolic Mdm2, which in turn can bind to and ubiquitinilate GRK2, thus 
promoting its degradation. To test this hypothesis, Mdm2 protein levels were quantified in 
the cytosolic and nuclear compartments of OPCs upon treatment with RAPA. Western-blot 
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analysis (Fig. 3C) showed that RAPA enhanced Mdm2 cytosolic levels while reducing its 
nuclear concentrations, thus promoting its association to GRK2 with obvious consequences 
on GPR17 desensitization. 
 
Sequestration of GRK2 by Mdm2 prevents GPR17 desensitization and OL maturation  
We then reasoned that Nutlin-3 might also profoundly influence agonist-induced GPR17 
desensitization and OPC terminal maturation. Hence, we exposed OPCs to LTD4 for 5-120 
min, a condition normally resulting in a time-dependent loss of GPR17 activity (Figure 2C), 
in absence or presence of Nutlin-3. As expected, in control treated cells (CTRL), prolonged 
exposure to LTD4 resulted in progressive GPR17 desensitization (white columns in Figure 
4A). In Nutlin-3-treated cells, GPR17 response to LTD4 was fully preserved, confirming that 
under these conditions GRK2 is no longer available for GPR17 desensitization (black 
columns in Figure 4A). Conversely, in line with the inability of Mdm2 to associate to GRK5 
(Figure 3B), UDP-glucose induced a similar time-dependent loss of GPR17 response in both 
the absence (CTRL) and presence of Nutlin-3 (white and black columns in Figure 4B). We 
conclude that dissociation of Mdm2-p53 complexes by Nutlin-3 enhances Mdm2-mediated 
GRK2 degradation, with consequent decreases of GRK2 levels and block of LTD4-induced 
GPR17 desensitization.  
To establish whether these effects also correlate with OPC differentiation, cells were 
first exposed to Nutlin-3 and then treated with LTD4 to promote OPC maturation. As 
expected, LTD4 increased the number of mature MBP-positive cells (Figure 4C). In the 
presence of Nutlin-3, LTD4-induced OPC maturation was reduced (Figure 4C) in line with 
the block of GPR17 desensitization under these settings (Figure 4A). We also observed a 
small, but statistically significant, decrease of OPC maturation when Nutlin-3 was applied to 
cells in the absence of LTD4 (Figure 4C), to suggest a modulation of the effects induced by 
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endogenous GPR17 agonists. These data confirm that: (i) increased Mdm2 association to 
GRK2 reduces the ability of this kinase to desensitize GPR17, and that (ii) the GRK2-GPR17 
interaction is required to complete OPC maturation.  
Overall, results show that the Mdm2 ligase intertwines mTOR with GRK2 in regulating the 
GPR17 receptor and OPC maturation, thus unveiling a totally unexpected role for Mdm2 in 
oligodendrogenesis and myelination (Figure 6). 
 
Postnatal in vivo treatment with RAPA increases GPR17 levels and reduces both GRK2 
and myelin proteins 
In rodents, myelination occurs in early postnatal life (Hamano et al., 1996) and is 
completed by post-natal day (P) 21. After birth, GPR17 expression is progressively increased 
to reach maximal peaks at P14 (Boda et al., 2011), after which it is progressively decreased 
reaching lower stable levels typical of adult life. Consistent with GPR17 anticipating 
myelination (Chen et al., 2009), massive myelin production followed the peak of GPR17
+
 
cell density (P7–P14) and occurred concomitantly with the decrease in GPR17
+
 cell number 
(Boda et al., 2011). If the relationships between mTOR, GRK2 and GPR17 detected in 
cultured OPCs are physiologically relevant, an early in vivo postnatal inhibition of mTOR 
should affect the normal maturation pattern of myelin proteins and also impact on cerebral 
GPR17 levels. We thus treated mice with either vehicle or RAPA (10 mg/Kg) (Guardiola-
Diaz et al., 2012) daily from P16 to P20 (Supplementary Figure S3A), a time window during 
which GPR17 starts to be down-regulated (Boda et al., 2011). As expected from literature 
data (Caccamo et al., 2010), RAPA-injected mice displayed a marked reduction of mTOR 
phosphorylation on Ser2448, to confirm that in vivo RAPA-treatment successfully inhibited 
mTOR activity (Figure 5). Under these conditions, a statistically significant increase in 
GPR17 levels was found in parallel to a reduction of both GRK2 and mature myelin proteins 
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like CNPase and MBP was found in parallel to increased GPR17 levels (Supplementary 
Figure 5B). These data fully confirm in vivo the relationships between mTOR, GRK2, 
GPR17 and myelination, suggesting that mTOR regulates postnatal myelination by fine-
tuning GPR17 levels and that GPR17 phosphorylation/desensitization by GRK2 is crucially 
involved in physiological myelination. 
 
Discussion  
Here we show, for the first time, a role of the ubiquitin ligase Mdm2 in 
oligodendrogenesis and myelination. Specifically, we demonstrate that Mdm2 intertwines the 
mammalian target of RAPA, mTOR, and the receptor kinase GRK2 in regulating the 
desensitization/inactivation of the GPR17 receptor, a key actor in OPC maturation to 
myelinating phenotypes.   
Our previous studies highlighted GPR17 as an indispensable player in initiating OPC 
differentiation but also suggested down-regulation of the receptor is needed to complete 
cells’ maturation. Our previous studies also demonstrated that GPR17 down-regulation 
occurs via agonist-induced receptor internalization, leading to a very marked degradation of 
the agonist-receptor complex in lysosomes and only partial re-recycling of GPR17 to the 
plasma membrane. The amount of internalized degraded receptor increased as a function of 
time of agonist exposure, suggesting that receptor re-routing to the membrane may be rather 
limited after long exposure times and/or at high agonist concentrations (Fratangeli et al., 
2013). 
Here, we first unequivocally confirmed that (Chen et al., 2009; Daniele et al., 2014) in 
cultured OPCs, forced GPR17 expression throughout their entire differentiation cycle impairs 
cells’ maturation. Accordingly, mice aberrantly over-expressing GPR17 under the control of 
the promoter of CNPase, a relatively late stage marker, displayed myelin dysfunctions, 
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tremors and precocious death (Chen et al., 2009). Moreover, in various neurodegeneration 
animal models, OPCs over-expressing GPR17 accumulate at lesion sites (Boda et al., 2011; 
Chen et al., 2009; Lecca et al., 2008).  
We then showed that RAPA-induced mTOR inhibition resulting in aberrant GPR17 up-
regulation and reduced OPC differentiation is mediated by GRK2. Indeed, in late OPCs, a 
reduction of GRK2 expression/activity by RAPA impaired both GPR17 desensitization and 
OPC maturation (Daniele et al., 2014), suggesting that loss of this kinase (that normally 
phosphorylates and down-regulates membrane receptors) may be responsible for the 
persistent GPR17 up-regulation (Daniele et al., 2014). To support the relevance of these 
findings to an in vivo situation, postnatal treatment of mice with RAPA induced a cortical 
reduction of myelin-related proteins MBP and CNPase, confirming that mTOR signalling is 
required during myelination active phases (Narayanan et al., 2009). These effects were 
associated to an in vivo increase of GPR17 levels and a reduction of GRK2, suggesting a 
failure of GPR17 down-regulation, likely due to loss of mTOR control on GRK2. Of course, 
since mTOR is such a central signaling hub affecting simultaneously many different 
pathways, we cannot exclude that, especially in vivo, RAPA is also inducing other effects. 
The crosstalk between mTOR and GRKs (Cobelens et al., 2007; Salcedo et al., 2006) in 
OPCs has never been investigated before. To address this issue, we focused on Mdm2, an 
ubiquitin ligase known for controlling p53 degradation and cancer malignancy (Ashcroft and 
Vousden 1999). In various types of human cancers, Mdm2 serves as an ubiquitin ligase that 
promotes p53 degradation, thus Mdm2 inhibitors are currently being evaluated in clinical 
trials as new anticancer drugs (Vassilev et al., 2004; Zhao et al., 2015). Based on these 
findings and of interest for our study, in MCF7 cells, a breast cancer cell line, a potential link 
between mTOR, Mdm2 and GRKs was suggested by the demonstration that, in response to 
the IGF-1 growth factor, Mdm2 phosphorylation by Akt kinase (which is part of the mTOR 
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pathway) stimulated GRK2 translocation from cytoplasm to nucleus and impaired Mdm2-
dependent GRK2 degradation (Feng et al., 2004; Mayo and Donner 2001; Salcedo et al., 
2006). Prompted by these findings, to investigate the potential involvement of Mdm2 in 
oligodendrogenesis, we demonstrated that, in immature OLs, a pool of endogenous GRK2 
and Mdm2 indeed co-immunoprecipitated in the same molecular complex. More relevant, 
inhibition of mTOR by RAPA markedly increased GRK2/Mdm2 association. Moreover, 
likely due to Mdm2 increased availability, disruption of the p53-Mdm2 complex by Nutlin-3 
potentiated GRK2/Mdm2 association, sequentially leading to (i) decreased GRK2 levels, (ii) 
reduced GRK2-GPR17 interaction after LTD4 stimulation, (iii) inhibition of LTD4-induced 
GPR17 desensitization and, (iv) impaired OPC maturation. These effects were specific for 
LTD4, since Nutlin-3 did not affect UDP-glucose-induced GPR17 desensitization. Based on 
these data, we speculate that, similarly to other disorders (i.e., rheumatoid arthritis (Lombardi 
et al., 1999; Taranto et al., 2005), low levels of GRK2 under demyelinating conditions may 
be due to a primary functional change of Mdm2, thus unveiling this ligase as a new player in 
OPCs terminal differentiation.  
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Figure legends 
 
Figure 1. mTOR inhibition by rapamycin impairs OPC maturation and increases 
GPR17 protein levels. (A) The scheme shows the experimental protocol of RAPA treatment 
and the different stages of OPC differentiation, starting from early oligodendrocyte 
precursors (stage 1) to mature OLs (stage 5). RAPA treatment was started at day 1 and 
differentiation media with or without RAPA was replenished every 72h. In most cases, 
analysis was performed at stage 4 and 5 (red circles); the outcome of these experiments is 
shown in the text. (B) Primary purified OPCs were cultured in the presence of PDGF and of 
bFGF for two days. Cell differentiation was induced by adding T3 to the medium. RAPA (15 
nM) was added at day 1 and day 4. At day 6 (mature OLs, stage 5), cells were fixed for ICC 
analysis or lysed for WB analysis. Representative images of CTRL and RAPA treated-cells, 
showing double immunostaining with anti-GPR17 (green) and anti-MBP (red) antibodies. 
Histograms show the quantification of the percentage of GPR17 and MBP positive cells in 
control and treated cells (with vehicle-treated control cells set to 100%). Hoechst 33258 was 
used to label cell nuclei. The number of positive cells was counted in 10 optical fields under a 
20X magnification. Data are the mean ± S.E. of cell counts from a total of 3 
coverslips/condition from three independent experiments, **p <0.01; ***p <0.001 compared 
to CTRL, Student t-test. (C) Representative immunoblots of GPR17, CNPase and MBP 
protein levels in CTRL and RAPA treated-cells. Histograms show the results of densitometric 
analysis. Scanning densitometry was quantified and normalized to control (set to 100%) on 
the same WB. α-tubulin expression was analysed from the same samples as an internal 
control. Data are expressed as mean ± S.E. of three independent experiments. *p <0.05; **p 
<0.01; compared to CTRL, non parametric Mann-Whitney test. (D) Primary OPCs were 
transfected with a GPR17-EGFP fusion vector for GPR17 over-expression or with the control 
plasmid (containing EGFP only). After 48/72h, cells were fixed and stained for CNPase 
Page 26 of 85
John Wiley & Sons, Inc.
GLIA
 26
(red). Scale bar 20µm. The percentage of transfected cells expressing CNPase over the total 
transfected cell population in the two conditions analysed was shown in the histogram. 
Forced GPR17 over-expression throughout differentiation stages significantly impairs 
spontaneous cell maturation ***p <0.001 compared to control, Student’s t-test, from 4 
independent experiments. 
 
Figure 2. GRK2 plays a key role in mTOR regulation of GPR17 function and OL 
maturation. (A) Representative immunoblots of GRK2 protein levels in CTRL and in RAPA 
treated cells. Histograms show the result of densitometric analysis. Scanning densitometry 
was quantified and normalized to control (set to 100%) on the same WB. α-tubulin 
expression was analysed from the same samples as an internal control. Data from two 
independent experiments were shown (mean ± S.E., *p <0.05 compared to CTRL, non 
parametric Mann-Whitney test). (B) Primary OPCs were treated with medium alone (basal), 
5 µM UDP-glucose, or 50 nM LTD4, in the absence (CTRL) or in the presence of 15 nM 
RAPA. Cell lysates (30 µg) were captured on wells pre-coated with anti-GPR17 antibody. 
After extensive washes, levels of GPR17/GRK2 complexes were quantified using a specific 
anti-GRK2 antibody. Data are the mean ± S.E. of two independent experiments. One-way 
ANOVA followed by Bonferroni post-test: *p < 0.05, ***p <0.001 vs. basal value. (C) 
OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 nM 
LTD4 for different times (5-120 min), in the absence (white bars, CTRL) or in the presence 
(black bars) of 15 nM RAPA. After extensive washing, cells were treated for 15 min with 10 
µM FK, in the absence or in the presence of 5 nM LTD4. Intracellular cAMP levels were 
evaluated as reported in Materials and Methods. Data are expressed as the percentage of FK-
stimulated cAMP levels, set to 100%, and represent the mean ± S.E. of three independent 
experiments: *p <0.05, ***p <0.001 vs LTD4 stimuli, #p <0.05, ###p <0.001 vs relative 
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control cells, one-way ANOVA followed by Bonferroni post-test. (D) OPCs were 
electroporated with a GRK2 encoding plasmid. GRK2 over-expression was verified by WB 
(see the representative immunoblots). 30 h after transfection, cells were treated with 50 nM 
LTD4 for different times (30-120 min), in the absence (white bars, CTRL) or presence of 15 
nM RAPA (black bars). After extensive washing, cells were treated for 15 min with 10 µM 
FK, in the absence or in the presence of 5 nM LTD4 and intracellular cAMP levels were 
evaluated. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, 
and represent the mean ± S.E. of two independent experiments. *p <0.05, **p <0.01, ***p 
<0.001 vs LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test.  
 
Figure 3. The ubiquitin ligase Mdm2 mediates the interaction between GRK2 and 
mTOR. Primary OPCs were pre-incubated for 15 min with 15 nM RAPA (A) or 10 µM NUT 
(B) and treated with medium alone (basal), or UDP-glucose (5 µM) or with LTD4 (50 nM), 
respectively for 30 min. Cell lysates (30 µg) were captured on wells pre-coated with anti-
Mdm2 antibody. After extensive washes, levels of Mdm2/GRK complexes were quantified 
using specific anti-GRK2 or anti-GRK5 antibodies, and subsequently an HRP-conjugated 
antibody/TMB substrate kit. Blank wells were obtained in the absence of the primary anti-
GRK antibodies. Data are expressed as fold vs. basal, and represent the mean ± S.E. of at 
least three independent experiments. **p < 0.01; ***p < 0.001 vs. basal value, one-way 
ANOVA with Bonferroni post-test. (C) Primary OPCs (stage 3) were treated with medium 
alone (CTRL) or 15 nM RAPA for 30 min. At the end of the treatment period, cytosolic and 
nuclear fractions were collected. Representative immunoblots of Mdm2 levels in CTRL and 
in RAPA-treated cells. Histograms show the result of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-
actin and hystone H3 expression were analysed from the same samples as loading controls 
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for the cytosolic and nuclear fraction, respectively. Data are expressed as mean ± S.E. of two 
independent experiments. One-way ANOVA followed by Bonferroni post-test: ***p <0.001 
compared to CTRL  (D) Representative immunoblots of GRK2 and GPR17 and CNPase 
protein levels in CTRL and in Nutlin-3 (NUT) treated cells. Histograms show the result of 
densitometric analysis. Scanning densitometry was quantified and normalized to control (set 
to 100%) on the same WB. α-tubulin expression was analysed from the same samples as an 
internal control. Data are expressed as mean ± S.E. of two independent experiments, *p <0.05 
compared to CTRL, non parametric Mann-Whitney test. (E) Primary OPCs were treated with 
medium alone (basal), 5 µM UDP-glucose, or 50 nM LTD4, in the absence (control) or in the 
presence of 10 µM NUT. Cell lysates (30 µg) were captured on wells pre-coated with anti-
GPR17 antibody. After extensive washes, levels of GPR17/GRK complexes were quantified 
using a specific anti-GRK2 antibody. Data are the mean ± S.E. of two independent 
experiments. Statistical significance was determined with a one-way ANOVA with 
Bonferroni post-test: *p < 0.05, ***p < 0.001 vs. basal value; #p < 0.05, ##p <0.01, ###p 
<0.001 vs. respective CTRL.  
 
Figure 4. Sequestration of GRK2 by Mdm2 prevents GPR17 desensitization and OL 
maturation. (A) OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were 
treated with 50 nM LTD4 or 5 µM UDP-glucose (B) for different times (5-120 min), in the 
absence (white bars, CTRL) or presence of 10 µM NUT (black bars). After extensive 
washing, cells were treated for 15 min with 10 µM FK, in the absence or in the presence of 
500 nM UDP-glucose or 5 nM LTD4 and intracellular cAMP levels were evaluated. Data are 
expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the 
mean ± S.E. of three independent experiments. *p <0.05, **p <0.01, ***p <0.001 vs UDP-
glucose or LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test. (C) Primary 
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purified OPCs were cultured in the presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 to the medium. NUT (1 µM) was added at day 1, 30 
minutes before treating cells with LTD4 (100 nM) or with vehicle. The differentiation degree 
of cells was monitored by analysing the number of cells expressing MBP at stage 4. 
Representative images of control (CTRL), NUT, LTD4 and NUT+LTD4 showing 
immunostaining with anti-MBP antibody (red). Histograms show the quantification of the 
percentage of MBP
+ 
cells in control and treated cells (with vehicle-treated control cells set to 
100%). Hoechst 33258 was used to label cell nuclei. The number of MBP
+
-cells was counted 
in the entire coverslip under a 40X magnification. Data are the mean ± S.E. of cell counts 
from a total of 3 coverslips/condition from three independent experiments *p <0.05; **p 
<0.01 compared to CTRL, ##p <0.01 compared to LTD4, non parametric Mann-Whitney test. 
 
Figure 5. Postnatal in vivo mTOR inhibition with rapamycin alters the normal 
development of GPR17, GRK2 and myelin associated proteins. (A) The drawing shows 
the experimental plan for the in vivo treatment. C57BL6/J mice were injected daily with 
either vehicle (3 animals) or rapamycin (3 animals) intraperitoneally at a dose of 10 mg/kg 
body weight, starting from postnatal day (P) 16 to P20. On P21, mice were sacrificed, brains 
extracted, rapidly frozen at -80°C and processed for western-blot analysis. (B) Representative 
immunoblots of phospho-mTOR, mTOR, GPR17, GRK2, CNPase and MBP protein levels in 
control (CTRL) and rapamycin (RAPA) treated mice. Histograms show the result of 
densitometric analysis. Scanning densitometry was quantified and normalized to control 
condition (set to 100%) on the same western blot membrane. α-tubulin expression was 
analysed from the same samples as an internal control. Data are expressed as mean ± S.E. *p 
<0.05; compared to CTRL, non parametric Mann-Whitney test. 
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Figure 6. A cartoon illustrating the signalling pathways involved in GPR17 
desensitization/down-regulation and OPC maturation. (A) Under conditions leading to 
physiological activation of the mTOR pathway, Mdm2 is mainly associated to the nucleus 
and bound to p53 and does not interfere with GRK2-mediated GPR17 desensitization in 
response to LTD4. (B) Inhibition of mTOR by rapamycin induced a redistribution of the 
intracellular concentrations of Mdm2, reducing its nuclear interaction with p53 and 
increasing the Mdm2/GRK2 association, causing a reduction of the expression levels of 
GRK2 and a subsequent loss in GPR17 desensitization in response to LTD4. The latter event 
impairs OPC maturation. To confirm the role of Mdm2 in GPR17 desensitization, Nutlin-3, 
releasing Mdm2 from its complex with p53, favoured the degradation of GRK2 mediated by 
Mdm2 and contributed to the impairment in thus impairing GPR17 desensitization and OPC 
maturation. 
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Abstract  
During oligodendrocyte precursor cell (OPC) differentiation, defective control of the 
membrane receptor GPR17 has been suggested to block cell maturation and impair re-
myelination under de-myelinating conditions. 
After the immature oligodendrocyte stage, to enable cells to complete maturation, 
GPR17 is physiologically down-regulated via phosphorylation/desensitization by G protein-
coupled Receptor Kinases (GRKs); conversely, GRKs are regulated by the “mammalian 
target of rapamycin” mTOR. However, how GRKs and mTOR are connected to each other in 
modulating GPR17 function and oligodendrogenesis has remained elusive. 
Here we show, for the first time, a role for Murine double minute 2 (Mdm2), a ligase 
previously involved in ubiquitination/degradation of the onco-suppressor p53 protein. In 
maturing OPCs, both rapamycin and Nutlin-3, a small molecule inhibitor of Mdm2-p53 
interactions, increased GRK2 sequestration by Mdm2, leading to impaired GPR17 down-
regulation and OPC maturation block. Thus, Mdm2 intertwines mTOR with GRK2 in 
regulating GPR17 and oligodendrogenesis and represents a novel actor in myelination. 
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Introduction  
Remyelination after central nervous system (CNS) insults is needed to re-establish nerve 
conduction and prevent axonal loss. Spontaneous remyelination based on recruitment and 
proliferation of oligodendrocyte precursor cells (OPCs) is defective in diseases such as 
multiple sclerosis, mainly due to an OPC differentiation block (Franklin and Ffrench-
Constant 2008; Kuhlmann et al., 2008). Identifying the mechanisms involved in defective 
OPC differentiation is important for developing new remyelinating strategies.  
The P2Y-like GPR17 receptor responding to uracil-nucleotides and cysteinyl-
leukotrienes (cysLTs), two families of mediators involved in CNS repair (Ciana et al., 2006), 
is a key regulator of OPC maturation (Chen et al., 2009; Coppi et al., 2013; Lecca et al., 
2008). GPR17 is expressed by a subpopulation of early OPCs and it is needed to start 
differentiation; however, GPR17 is turned down before cells reach maturation (Fumagalli et 
al., 2011). GPR17 responses are regulated by its endogenous ligands; by binding to the 
receptor, ligands first induce OPCs to undergo differentiation and then switch GPR17 off, 
inducing its desensitization/down-regulation and cytoplasmic internalization. These latter 
events involve specific isoforms of G-protein-coupled receptor kinases (GRKs), either GRK2 
or GRK5, depending on the class of ligand bound to the receptor (Daniele et al., 2014). 
Alterations of GPR17 activation and physiological silencing at specific OPC differentiation 
phases may lead to myelination defects and be even at the basis of demyelinating diseases. 
In various in vivo neurodegenerative models characterized by myelin loss (stroke, 
trauma, demyelination and experimental autoimmune encephalomyelitis), GPR17 was 
abnormally up-regulated in OPCs around lesion sites (Boda et al., 2011; Chen et al., 2009; 
Lecca et al., 2008). Accordingly, we recently reported that decreased GRKs levels resulting 
in defective GPR17 desensitization markedly reduce OPC maturation (Daniele et al., 2014). 
Of interest, altered GRKs expression/activity has been implicated in human inflammatory 
and demyelinating diseases (Gurevich et al., 2012; Vroon et al., 2005). 
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GRKs alterations may, in turn, depend on mTOR (the “mammalian target of 
rapamycin”), a serine/threonine protein-kinase inhibited by the immunosuppressive agent 
rapamycin (RAPA). mTOR is central to cell growth, differentiation and survival and has been 
implicated in oligodendrocyte (OL) development and myelination (Tyler et al., 2009). 
Interestingly, a recent proteomic analysis highlighted increased levels of GPR17 in RAPA–
treated OPCs, suggesting this receptor as a putative target for mTOR (Tyler et al., 2011). 
Despite this initial evidence, the relationships between mTOR, GRKs, GPR17, its interacting 
proteins and OL maturation have remained elusive. 
Here, we demonstrate that, in rat primary OPCs, inhibition of mTOR by RAPA reduces 
GRK2 levels and prevents GPR17 down-regulation/desensitization, strongly inhibiting OPC 
maturation. We also prove, for the first time, that Mdm2 (Murine double minute-2), a ligase 
previously involved in the ubiquitination/degradation of the onco-suppressive p53 protein 
and in tumor progression (Ashcroft and Vousden 1999) specifically controls OPC maturation 
by intertwining mTOR with GRK2.  
 
Materials and Methods 
Oligodendrocyte precursor cell cultures 
Primary OPCs were isolated from mixed glial cultures prepared from postnatal day 2 
Sprague–Dawley rat cortex by shaking cells on an orbital shaker at 200 rpm, as previously 
described (Fumagalli et al., 2011). OPCs were then collected and separated from microglia 
by incubation for 1h on an uncoated Petri dish. Purified OPCs were seeded onto poly-D,L-
ornithine-coated glass coverlisps or plates (50 µg/ml, Sigma-Aldrich, Milan, Italy) to a 
specific density according to the planned experiments (see below), in Neurobasal (Life 
Technologies, Monza, Italy) with 2% B27 (Life Technologies), 2 mM L-glutamine 
(EuroClone), 10 ng/ml human platelet-derived growth factor BB (Sigma-Aldrich), and 10 
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ng/ml human basic fibroblast growth factor (Space Import Export, Milan, Italy), to promote 
proliferation. After 2 day, cells were switched to a Neurobasal medium lacking growth 
factors to allow differentiation. In some experiments triiodothyronine T3 (Sigma Aldrich) 
was also added to a final concentration of 10 ng/ml.  
 
In vitro pharmacological treatments 
According to the planned experiments, cells were plated in 13 mm glass coverslip or in 60 
mm diameter petri dish (20,000 cells/coverslip or 100,000 cells/dish) maintained for 2 days in 
Neurobasal supplemented with B27 and proliferative factors (PDGF-BB and bFGF) and then, 
after one day in differentiating medium, cells were treated with either rapamycin (15 nM) 
(Sigma-Aldrich) or with Nutlin-3 (NUT, 1 µM) (Sigma Aldrich). Cells were fixed for 
immunocytochemistry (ICC) or lysed for WB analysis at day 4 or 6 (see also figure legends 
for details).  
 
Generation of pGPR17-EGFP-N1 plasmid and OPC transfection  
The coding sequence of the human GPR17 receptor was subcloned from a previously 
generated pcDNA3.1 vector (Life Technologies), using specific primers containing the 
restriction cassette for XhoI and BamHI (fw: 5’-gttttttctcgagatgaatggccttgaagtggc; rv: 5’-
ggtggatccgacagctctgacttggcactca). The product was then inserted upstream to the EGFP 
sequence in a pEGFP-N1 expression vector (Clontech). For GPR17 over-expression in OPCs, 
cells were seeded on 13 mm poly-D,L-ornithine-coated coverslips (2 x 10
4
 cells/well) in 
Neurobasal supplemented with B27 and proliferative factors (PDGF-BB and bFGF). 
Differentiation was then, induced by removing proliferative factors and at day 4, cells were 
transfected with the fluorescent plasmid pGPR17-EGFP, in parallel to the corresponding 
fluorescent empty vector, using the transfection reagent NeuroFECT
TM
 (Genlantis, San 
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Diego, CA, USA) according to manufacturer's protocol. After transfection, cells were 
maintained in differentiating medium supplemented with T3 for additional 48-72 hours and 
fixed for ICC. 
 
OPCs electroporation with a GRK2 plasmid 
GRK2 overexpression was obtained by electroporating OPCs with the Amaxa Rat 
Oligodendrocyte Nucleofection Kit (Lonza, Milan, Italy) according to the manufacture’ 
instructions. In detail, OPCs were electroporated with 1 µg either of GRK2 plasmid 
(Origene) or the corresponding empty vector (OriGene, Maryland, USA) with the O-017 
program. After electroporation, cells were rapidly seeded on 13 mm poly-D,L-ornithine-
coated coverslips (5 x 10
4
 cells/well) in Neurobasal supplemented with B27 and proliferative 
factors (PDGF-BB and bFGF) and maintained in this medium. In parallel, electroporated 
OPCs were also seeded on 60 mm poly-D,L-ornithine-coated dish in order to check 
transfection efficiency by western-blot analysis. After 30 hours, electroporated OPCs were 
subjected to the cAMP assay (see below)  
 
Immunocytochemistry 
Both primary OPCs and OPC-DRG co-cultures were fixed at room temperature with 4% 
paraformaldehyde (Sigma-Aldrich) in 0.1 M PBS (Euroclone) containing 0.12 M sucrose 
(Sigma-Aldrich). Labelling was performed incubating cells overnight at 4°C with the 
following primary antibodies in Goat Serum Dilution Buffer (GSDB; 450 mM NaCl, 20 mM 
sodium phosphate buffer, pH 7.4, 15% goat serum, 0.3% Triton X-100): rat anti-MBP (1:200; 
Millipore, Milan, Italy), rabbit anti-GPR17 (1:100; Cayman, Michigan, USA), mouse anti-
SMI 31 and mouse anti SMI 32 (1:500; Cell Signaling, Beverly, MA, USA). Cells were then 
incubated for 1h at RT with the secondary goat anti-rat, goat anti-rabbit or goat anti-mouse 
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antibody conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:600 in GSDB; Molecular 
Probes, Life Technologies). Nuclei were labelled Hoechst-33258 (1:10,000, Molecular 
Probes, Life Technologies). Coverslips were finally mounted with a fluorescent mounting 
medium (Dako, Milan, Italy) and analysed under a fluorescence or confocal microscope 
(LSM510 META, Zeiss). For cell count, 10 or 20 fields were acquired at 20X magnification 
(at least 3 coverslips for each experimental condition) under an inverted fluorescence 
microscope (200M; Zeiss) connected to a PC computer equipped with the Axiovision 
software (Zeiss). Images were collected and cells scored and counted using the ImageJ 
software.  
 
Subcellular localization of Mdm2 
Primary OPCs (stage 3) were treated with medium alone (CTRL) or 15 nM RAPA for 30 
min. At the end of treatments, cells were collected and suspended in 5 mM Tris-EDTA (pH 
7.4) and nuclear cell fractions were isolated by centrifugation at 1000 x g for 15 min at 4°C. 
Mdm2 levels were detected in both cytoplasmic and nuclear fractions by immunoblotting 
using an anti-Mdm2 antibody (Santa Cruz Biotechnology, sc-812; 1:100). GAPDH (Sigma 
Aldrich, G9545, 1:5000) and hystone H3 (Santa Cruz Biotechnology, sc-8654; 1:100) were 
analysed from the same samples as loading controls for the cytosolic and nuclear fraction, 
respectively. 
 
Western blot analysis  
Cell lysates were prepared and analysed by WB as previously described (Coppi et al., 2013). 
Briefly, cells were lysed in lysis buffer (20 mM Tris pH 7.2, 0.5% deoxycholate, 1% Triton, 
0.1% SDS, 150 mM NaCl, 1 mM EDTA and 1% proteases inhibitors, Sigma-Aldrich) and, 
then, approximately 25-30 µg aliquots from each protein sample were loaded on 12% 
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sodium-dodecylsulphate polyacrylamide gels (for MBP and CNPase) or on 8.5% sodium-
dodecylsulphate polyacrylamide gels (for GPR17, NG2, GRK2 and GRK5), and blotted onto 
nitrocellulose membranes (MBP and CNPase) or PVDF membranes (GPR17, GRK2, GRK5 
and NG2) (Bio-Rad Laboratories, Segrate, Milan, Italy). Membranes were saturated with 
10% non-fat dry milk in Tris-buffered saline (TBS; 1 mM Tris-HCl, 15 mM NaCl, pH 8) for 
1 h at room temperature and incubated overnight at 4°C with the following primary 
antibodies diluted in 5% non-fat dry milk in TBS: rabbit anti-GPR17 (1:1000, home-made 
antibody), rat anti-MBP (1:500), rabbit anti-CNPase (1:250; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), rabbit anti-GRK2 (sc-562, 1:200; Santa Cruz Biotechnology) and rabbit 
anti-GRK5 (sc-565, 1:200; Santa Cruz Biotechnology), rabbit anti-phospho mTOR (Ser2448) 
(1:500; Cell Signaling, Danvers, MA, USA), mouse anti-mTOR (1:1000; Cell Signaling). 
The following day, membranes were washed in TBS-T (TBS plus 0.1% Tween20® Sigma 
Aldrich), incubated for 1 h with goat anti-rabbit or goat anti-mouse or goat anti-rat secondary 
antibodies conjugated to horseradish peroxidase (1:4000, 1:2000 and 1:2000 in 5% non-fat 
dry milk in TBS respectively; Sigma-Aldrich). Detection of proteins was performed by 
enhanced chemiluminescence (ECL, Thermo Scientific, Rodano, Milan, Italy) and 
autoradiography. Non-specific reactions were evaluated in the presence of the secondary 
antibodies alone. Densitometric analysis of the protein bands was performed with ImageJ 
software. Band intensities were measured as integrated density volumes (IDV) and expressed 
as % of control lane values for comparisons between treatment groups. α-Tubulin (1:1500; 
Sigma Aldrich) or α-actin (1:5000; Sigma Aldrich) expression was analysed from the same 
sample as an internal control and it was used for data normalization. 
 
Measurement of cyclic AMP levels 
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For OPCs, cells were plated in 24 well-plates and after 6 days in culture in differentiation 
medium without T3, functional responsiveness of GPR17 was assessed as described, (Daniele 
et al., 2014; Fumagalli et al., 2011) using 500 nM UDP-glucose or 5 nM LTD4, as stimuli. 
For desensitisation experiments, OPCs were pre-treated with UDP-glucose (5 µM) or LTD4 
(50 nM) for different times (5-120 min), in the absence (control cells) or in the presence of 15 
nM rapamycin or 10 µM Nutlin-3. Then, cells were washed with 400 µl of saline and 
incubated at 37°C for 15 min with 0.4 ml of non-complete Neurobasal in the presence of the 
phosphodiesterase inhibitor, Ro20-1724 (20 µM) and stimulated with agonists (500 nM 
UDP-glucose or 5 nM LTD4), in the presence of 10 µM Forskolin (FK). Intracellular cAMP 
levels were measured using a competitive protein binding method, as previously reported 
(Daniele et al., 2014).  
 
ELISA assay for the detection of GPR17-GRK or Mdm2-GRK immunocomplexes 
OPCs were treated with medium alone (basal), or UDP-glucose (5µM) or with LTD4 (50 
nM), respectively for 30 min. In some experiments, cells were pre-incubated for 15 min with 
15 nM rapamycin or 10 µM Nutlin-3. Then, cells were washed twice in ice-cold phosphate-
buffered saline, collected by centrifugation, and resuspended in Lysis buffer (20 mM Tris 
HCl, 137 mM NaCl, 10% glycerol, 1% NONIDET40, 2 mM EDTA, pH 8), containing 1% of 
the Protease inhibitor Cocktail (Sigma Aldrich, Milan, Italy). Optimal composition of lysis 
buffer, as well as reaction conditions, were determined in preliminary experiments. Levels of 
GPR17-GRK or Mdm2-GRK immunocomplexes in OPC lysates, obtained as above 
described, were quantified using a validated ELISA method (Zappelli et al., 2014). 96-wells 
were pre-coated with a mouse full-length anti-Mdm2 antibody (sc-965, Santa Cruz 
Biotechnology, 1:50 in 0.05% Poly-L-Ornithine) or with an anti-N terminus GPR17 antibody 
(sc-74792, Santa Cruz Biotechnology, 1:50 in 0.05% Poly-L-Ornithine) overnight at room 
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temperature. After three washes of 5 minutes with 100 µl of PBS/Tween 0.1%, cell lysates 
(50 µg in a final volume of 100 µl) were transferred to the pre-coated wells for 120 min with 
a plastic cover or film and kept under constant agitation. Three quick washes were performed 
with PBS/Tween 0.1% to remove unbound protein, and each well was incubated for 15 min 
with 1% bovine serum albumin (BSA, Sigma) to block non-specific sites. Then, wells were 
incubated for 120 min at room temperature with the specific primary antibodies: anti-GRK2 
(Santa Cruz Biotechnology, sc-562; 1:400); anti-GRK5 (Santa Cruz Biotechnology, sc-565; 
1:400). Wells were washed and incubated for 1 h with a secondary HRP-conjugate antibody 
(diluted in 5% milk), and washed again. The TMB substrate kit (Thermo Fisher Scientific) 
allowed a colorimetric quantification of the complex of GRKs with GPR17 or Mdm2. Blanks 
were obtained processing cell lysates in the absence of the primary antibodies. To avoid cross 
interactions between the different antibodies, the chosen primary antibody was always from a 
different species with respect to the antibody used for well pre-coating. Absorbance’s values 
at 450 nm were measured, background subtracted and bar graphs were generated using Graph 
Pad Prism 4 software (GraphPad Software Inc., San Diego, CA), from which the percentage 
of association between the two analysed proteins, compared to basal value, were derived. 
 
In vivo rapamycin injections. 
C57BL6/J mice were injected daily with either vehicle or rapamycin intraperitoneally at 10 
mg/kg body weight (rapamycin was diluted in the vehicle solution from a stock of 20 mg/mL 
in 100% ethanol immediately before the injection to a final concentration of 0.8 mg/mL PBS, 
5% polyethylene glycol-1000, 5% Tween 80, and 4% ethanol) starting at postnatal day (P) 
16. On P21, mice were sacrificed, brains were extracted and rapidly frozen at -80°C. 
Membrane protein extracts were obtained by tissue homogenization in lysis buffer (20 mM 
Tris pH 7.2, 0.5% deoxycholate, 1% Triton, 0.1% SDS, 150 mM NaCl, 1 mM EDTA and 1% 
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proteases inhibitors, Sigma-Aldrich). The homogenate was centrifuged at 1000g for 10 min at 
4°C in order to eliminate nuclei. The protein concentration was estimated using the Bio-Rad 
Protein Assay (Bio-Rad Laboratories s.r.l., Segrate, Italy). Western blot analysis was 
performed as described below. 
 
Statistical analysis 
All results were expressed as mean ± S.E. Statistical analysis was done with non-linear 
multipurpose curve-fitting Graph-Pad Prism program (Graph-Pad). The statistical test used 
was chosen according to the type of experiment performed and was indicated in the legend of 
the figure. Three degrees of significance were considered: P<0.05 (*), P< 0.01 (**), P < 
0.001 (***). 
 
Results 
Involvement of mTOR in GPR17 regulation during OPC differentiation 
Cultured OPCs are known to undergo different subsequent stages of differentiation 
(stages 1-5) when maintained for up to 6 days in vitro (DIV6) when they reach terminal 
maturation (stage 5 in Figure 1A). Initial data from a proteomic analysis had shown that 
RAPA increases GPR17 levels in parallel to a reduction of OPC maturation, highlighting 
GPR17 as a potential target for mTOR and suggesting that receptor silencing is required for 
OPC terminal maturation (Ceruti et al., 2011; Fumagalli et al., 2011; Lecca et al., 2008). To 
get more insights in mTOR regulation of GPR17 and on its effects on OPC maturation, as a 
first step, we performed a detailed immunocytochemical and western blot (WB) analysis of 
GPR17 in OPCs treated with RAPA from DIV1 and analysed at either DIV4 (Supplementary 
Figure S1A) or DIV6 (Figure 1B). At DIV6 (stage 5), RAPA markedly reduced the number 
of terminal MBP
+
 OLs and concomitantly increased the number of GPR17
+
 cells (Figure 1B). 
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No changes in total cell number were detected (CTRL: 527.4 ± 73.64; RAPA: 412.6 ± 55.59, 
Hoechst 33258 staining). WB analysis confirmed a significant GPR17 enhancement in 
parallel with reduced mature myelin proteins (CNPase and MBP) (Figure 1C). As shown in 
Supplementary Figure S1A, in RAPA-treated cells, an increase (+38.7%) of GPR17 
compared to CTRL was already detected at DIV4 (stage 4), together with reductions of 
CNPase and MBP. Conversely, RAPA had no effect on GPR17 at DIV3 (data not shown). To 
confirm that the effects of RAPA on OPC maturation indeed result in impairments of 
myelination, RAPA-treated cultures also showed a reduction of MBP
+
 segments extending 
along neurofilament (NF)-positive axons in neuronal/OPC co-cultures (Supplementary Figure 
S1B). To univocally endorse that GPR17 down-regulation is needed for OPC terminal 
maturation, we then transfected OPCs with a fluorescence reporter plasmid for GPR17 over-
expression (GPR17-EGFP). After 3 days, the majority of control OPCs incorporating the 
empty plasmid underwent maturation, as demonstrated by CNPase expression and large 
cytoplasmic areas with many branched processes (Figure 1D). Conversely, most OPCs 
incorporating the vector for GPR17 over-expression kept an immature morphology and 
showed reduced expression of both CNPase (Figure 1D) and MBP (data not shown). Thus, 
interference with GPR17 down-regulation resulting in permanently elevated GPR17 levels 
markedly impairs OPC differentiation.  
 
GRK2 plays a key role in mTOR regulation of GPR17 function and OL maturation 
In other cells, mTOR regulates the expression/function of membrane GPCRs by 
modulating GRKs (Cobelens et al., 2007). We previously showed that, in OPCs, GRKs are 
involved in GPR17 desensitization/internalization induced by prolonged exposure to its 
agonists, and that, depending on the type of ligand (either LTD4 or UDP-glucose), different 
GRKs (namely, GRK2 or GRK5) are preferentially recruited to regulate GPR17 functional 
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response (Daniele et al., 2014). 
To establish a functional relationship between mTOR and GRK in OPCs, we analysed the 
expression profile of these GRK isoforms at DIV4 and DIV6 in control and RAPA-treated 
cells. RAPA significant decreased GRK2 levels (Figure 2A), whereas no changes in GRK5 
were observed (Supplementary Figure S3A). Then, based on previous data showing that 
GPR17 associates to GRK2 to a higher extent after LTD4 compared to UDP-glucose (Daniele 
et al., 2014) (see also Figure 2B), we measured GPR17-GRK2 association in OPCs in 
absence or presence of RAPA, and after either LTD4 or UDP-glucose exposure. Consistent 
with data in Figure 2A, association of GPR17 to GRK2 was significantly decreased by 
RAPA, particularly when LTD4 was used to activate GPR17 (Figure 2B). GPR17 is coupled 
to Gi and its activation by agonists consequently results in marked inhibition of intracellular 
levels of cAMP (Fumagalli et al., 2011). Accordingly, in OPCs, LTD4 potently reduces the 
increases of cAMP levels induced by the cyclase activator FK (Figure 2C). This Gi mediated 
effect was progressively lost in cells exposed to the agonist for prolonged time periods, 
suggesting receptor desensitization (white columns in Figure 2C). RAPA markedly prevented 
LTD4 induced receptor desensitization despite an initial challenge with this agonist (black 
columns in Figure 2C), likely due to a decrease in GRK2 levels. In contrast, UDP-glucose, 
which activates the GRK5-dependent pathway (Daniele et al., 2014) still induced GPR17 
desensitization with kinetics similar to control OPCs (Supplementary Figure S3B). These 
results suggest that mTOR regulates GRK2 which, in turn, mediates LTD4-induced GPR17 
desensitization. To further confirm this hypothesis and unequivocally relate RAPA-induced 
decrease in GRK2 levels with loss of GPR17 desensitization, we performed “rescue 
experiments” by over-expressing GRK2 in OPCs. Electroporation of cells with a GRK2 
plasmid indeed resulted in a marked increase of GRK2 protein levels compared to the 
corresponding empty vector, as shown by western blot analysis (Fig. 2D). To make sure that 
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electroporation had no effects on GPR17 desensitization kinetics, we analyzed LTD4-
mediated loss of GPR17 function in cells electroporated with the corresponding empty 
vector. In a similar way to standard controls (Fig. 2C), pre-exposure of electroporated OPCs 
to LTD4 gradually desensitized GPR17, and, as expected, this effect was prevented by 
inhibiting mTOR with rapamycin (Supplementary Figure S2). On the contrary, in OPCs 
electroporated with the GRK2 plasmid, RAPA was no longer able to prevent LTD4-induced 
GPR17 desensitization (black columns compared to white columns in Fig. 2D). Globally, 
these results confirm that: (i) GRK2 is very important for LTD4-induced GPR17 
desensitization; (ii) mTOR normally controls GRK2 activation and GPR17 desensitization; 
(iii) inhibition of mTOR by RAPA results in prevention of GPR17 desensitization, but this 
effect is surmounted by GRK2 overexpression; (iv) GRK2 is downstream of mTOR in the 
pathway of GPR17 desensitization. 
 
 
The ubiquitin ligase Mdm2 mediates the interaction between GRK2 and mTOR 
To gain insights into mTOR-mediated mechanisms governing GRK2 levels/activity in 
OPCs, we analysed the involvement of the ubiquitin ligase Mdm2. This ligase normally acts 
as a negative regulator of the onco-suppressor p53 protein, but has also been reported to 
regulate membrane GPCRs by promoting the degradation of GRK2 in cells other than OPC 
(Freedman et al., 1999; Salcedo et al., 2006; Thut et al., 1997). On this basis, we quantified 
Mdm2-association to either GRK2 or GRK5 after mTOR inhibition. RAPA significantly 
enhanced Mdm2 association to GRK2 with no changes in Mdm2-GRK5 complexes, 
confirming that, in OPCs, Mdm2 is selective for GRK2 (Figure 3A and Supplementary 
Figure S5). These data are consistent with decreased GRK2 (Figure 2A) and unaltered GRK5 
levels in RAPA-treated OPC lysates (Supplementary Figure S3A). To more directly establish 
a functional link between Mdm2 and GRK2, we took advantage of Nutlin-3, a small-
Page 46 of 85
John Wiley & Sons, Inc.
GLIA
 16
molecule inhibitor of Mdm2-p53 interactions (Arva et al., 2008), thus making Mdm2 more 
available for association to GRK2. Nutlin-3 (NUT) markedly enhanced Mdm2-GRK2 
association, with negligible effects on the formation of Mdm2-GRK5 complexes (Figure 3B 
and Supplementary Figure S5). Sequestration of GRK2 by Mdm2 indeed resulted in a 
marked reduction of GRK2 levels (Figure 3C), suggesting that Mdm2 drives the 
ubiquitination/degradation of this kinase. A parallel increase of GPR17 together with 
decreased CNPase levels was also detected after Nutlin-3 (Figure 3D). In line with these data, 
Nutlin-3 markedly reduced the association of GRK2 to GPR17 after OPC exposure to GPR17 
agonists, with a more marked effect after LTD4 (Figure 3E). Globally, these data suggest that, 
in OPCs, disruption of Mdm2-p53 interaction favours the association of Mdm2 to GRK2 and 
its subsequent degradation, thus impairing GRK2 interaction with GPR17 (Figure 3E).  
 
mTOR regulates the equilibrium between Mdm2-p53 and Mdm2-GRK2 complexes  
The above data suggest that mTOR signaling would shift the equilibrium from Mdm2-
p53 association to Mdm2-GRK2 association, thereby allowing GRK2 to mediate GPR17 
desensitization and OPC maturation. To substantiate this hypothesis, we directly assessed the 
association of Mdm2 to p53 upon RAPA treatment. As shown in Fig. S4, pre-treatment of 
OPCs with either RAPA or Nutlin-3 for 30 min reduced the association between Mdm2 and 
p53. Since in other cells (e.g MCF-7 cells) mTOR dependent phosphorylation of Mdm2 
stimulates its translocation from the cytoplasm to the nucleus (Mayo et al., 2001; Feng et al., 
2004; Salcedo et al., 2006), where it then associates to p53, we reasoned that mTOR 
inhibition by RAPA could result in reduced levels of nuclear Mdm2 and in elevated 
expression of cytosolic Mdm2, which in turn can bind to and ubiquitinilate GRK2, thus 
promoting its degradation. To test this hypothesis, Mdm2 protein levels were quantified in 
the cytosolic and nuclear compartments of OPCs upon treatment with RAPA. Western-blot 
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analysis (Fig. 3C) showed that RAPA enhanced Mdm2 cytosolic levels while reducing its 
nuclear concentrations, thus promoting its association to GRK2 with obvious consequences 
on GPR17 desensitization. 
 
Sequestration of GRK2 by Mdm2 prevents GPR17 desensitization and OL maturation  
We then reasoned that Nutlin-3 might also profoundly influence agonist-induced GPR17 
desensitization and OPC terminal maturation. Hence, we exposed OPCs to LTD4 for 5-120 
min, a condition normally resulting in a time-dependent loss of GPR17 activity (Figure 2C), 
in absence or presence of Nutlin-3. As expected, in control treated cells (CTRL), prolonged 
exposure to LTD4 resulted in progressive GPR17 desensitization (white columns in Figure 
4A). In Nutlin-3-treated cells, GPR17 response to LTD4 was fully preserved, confirming that 
under these conditions GRK2 is no longer available for GPR17 desensitization (black 
columns in Figure 4A). Conversely, in line with the inability of Mdm2 to associate to GRK5 
(Figure 3B), UDP-glucose induced a similar time-dependent loss of GPR17 response in both 
the absence (CTRL) and presence of Nutlin-3 (white and black columns in Figure 4B). We 
conclude that dissociation of Mdm2-p53 complexes by Nutlin-3 enhances Mdm2-mediated 
GRK2 degradation, with consequent decreases of GRK2 levels and block of LTD4-induced 
GPR17 desensitization.  
To establish whether these effects also correlate with OPC differentiation, cells were 
first exposed to Nutlin-3 and then treated with LTD4 to promote OPC maturation. As 
expected, LTD4 increased the number of mature MBP-positive cells (Figure 4C). In the 
presence of Nutlin-3, LTD4-induced OPC maturation was reduced (Figure 4C) in line with 
the block of GPR17 desensitization under these settings (Figure 4A). We also observed a 
small, but statistically significant, decrease of OPC maturation when Nutlin-3 was applied to 
cells in the absence of LTD4 (Figure 4C), to suggest a modulation of the effects induced by 
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endogenous GPR17 agonists. These data confirm that: (i) increased Mdm2 association to 
GRK2 reduces the ability of this kinase to desensitize GPR17, and that (ii) the GRK2-GPR17 
interaction is required to complete OPC maturation.  
Overall, results show that the Mdm2 ligase intertwines mTOR with GRK2 in regulating the 
GPR17 receptor and OPC maturation, thus unveiling a totally unexpected role for Mdm2 in 
oligodendrogenesis and myelination (Figure 6). 
 
Postnatal in vivo treatment with RAPA increases GPR17 levels and reduces both GRK2 
and myelin proteins 
In rodents, myelination occurs in early postnatal life (Hamano et al., 1996) and is 
completed by post-natal day (P) 21. After birth, GPR17 expression is progressively increased 
to reach maximal peaks at P14 (Boda et al., 2011), after which it is progressively decreased 
reaching lower stable levels typical of adult life. Consistent with GPR17 anticipating 
myelination (Chen et al., 2009), massive myelin production followed the peak of GPR17
+
 
cell density (P7–P14) and occurred concomitantly with the decrease in GPR17
+
 cell number 
(Boda et al., 2011). If the relationships between mTOR, GRK2 and GPR17 detected in 
cultured OPCs are physiologically relevant, an early in vivo postnatal inhibition of mTOR 
should affect the normal maturation pattern of myelin proteins and also impact on cerebral 
GPR17 levels. We thus treated mice with either vehicle or RAPA (10 mg/Kg) (Guardiola-
Diaz et al., 2012) daily from P16 to P20 (Supplementary Figure S3A), a time window during 
which GPR17 starts to be down-regulated (Boda et al., 2011). As expected from literature 
data (Caccamo et al., 2010), RAPA-injected mice displayed a marked reduction of mTOR 
phosphorylation on Ser2448, to confirm that in vivo RAPA-treatment successfully inhibited 
mTOR activity (Figure 5). Under these conditions, a statistically significant increase in 
GPR17 levels was found in parallel to a reduction of both GRK2 and mature myelin proteins 
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like CNPase and MBP (Figure 5B). These data fully confirm in vivo the relationships 
between mTOR, GRK2, GPR17 and myelination, suggesting that mTOR regulates postnatal 
myelination by fine-tuning GPR17 levels and that GPR17 phosphorylation/desensitization by 
GRK2 is crucially involved in physiological myelination. 
 
Discussion  
Here we show, for the first time, a role of the ubiquitin ligase Mdm2 in 
oligodendrogenesis and myelination. Specifically, we demonstrate that Mdm2 intertwines the 
mammalian target of RAPA, mTOR, and the receptor kinase GRK2 in regulating the 
desensitization/inactivation of the GPR17 receptor, a key actor in OPC maturation to 
myelinating phenotypes.   
Our previous studies highlighted GPR17 as an indispensable player in initiating OPC 
differentiation but also suggested down-regulation of the receptor is needed to complete 
cells’ maturation. Our previous studies also demonstrated that GPR17 down-regulation 
occurs via agonist-induced receptor internalization, leading to a very marked degradation of 
the agonist-receptor complex in lysosomes and only partial re-recycling of GPR17 to the 
plasma membrane. The amount of internalized degraded receptor increased as a function of 
time of agonist exposure, suggesting that receptor re-routing to the membrane may be rather 
limited after long exposure times and/or at high agonist concentrations (Fratangeli et al., 
2013).  
Here, we first unequivocally confirmed that (Chen et al., 2009; Daniele et al., 2014) in 
cultured OPCs, forced GPR17 expression throughout their entire differentiation cycle impairs 
cells’ maturation. Accordingly, mice aberrantly over-expressing GPR17 under the control of 
the promoter of CNPase, a relatively late stage marker, displayed myelin dysfunctions, 
tremors and precocious death (Chen et al., 2009). Moreover, in various neurodegeneration 
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animal models, OPCs over-expressing GPR17 accumulate at lesion sites (Boda et al., 2011; 
Chen et al., 2009; Lecca et al., 2008).  
We then showed that RAPA-induced mTOR inhibition resulting in aberrant GPR17 up-
regulation and reduced OPC differentiation is mediated by GRK2. Indeed, in late OPCs, a 
reduction of GRK2 expression/activity by RAPA impaired both GPR17 desensitization and 
OPC maturation (Daniele et al., 2014), suggesting that loss of this kinase (that normally 
phosphorylates and down-regulates membrane receptors) may be responsible for the 
persistent GPR17 up-regulation (Daniele et al., 2014). To support the relevance of these 
findings to an in vivo situation, postnatal treatment of mice with RAPA induced a cortical 
reduction of myelin-related proteins MBP and CNPase, confirming that mTOR signalling is 
required during myelination active phases (Narayanan et al., 2009). These effects were 
associated to an in vivo increase of GPR17 levels and a reduction of GRK2, suggesting a 
failure of GPR17 down-regulation, likely due to loss of mTOR control on GRK2. Of course, 
since mTOR is such a central signaling hub affecting simultaneously many different 
pathways, we cannot exclude that, especially in vivo, RAPA is also inducing other effects. 
The crosstalk between mTOR and GRKs (Cobelens et al., 2007; Salcedo et al., 2006) in 
OPCs has never been investigated before. To address this issue, we focused on Mdm2, an 
ubiquitin ligase known for controlling p53 degradation and cancer malignancy (Ashcroft and 
Vousden 1999). In various types of human cancers, Mdm2 serves as an ubiquitin ligase that 
promotes p53 degradation, thus Mdm2 inhibitors are currently being evaluated in clinical 
trials as new anticancer drugs (Vassilev et al., 2004; Zhao et al., 2015). Based on these 
findings and of interest for our study, in MCF7 cells, a breast cancer cell line, a potential link 
between mTOR, Mdm2 and GRKs was suggested by the demonstration that, in response to 
the IGF-1 growth factor, Mdm2 phosphorylation by Akt kinase (which is part of the mTOR 
pathway) stimulated GRK2 translocation from cytoplasm to nucleus and impaired Mdm2-
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dependent GRK2 degradation (Feng et al., 2004; Mayo and Donner 2001; Salcedo et al., 
2006). Prompted by these findings, to investigate the potential involvement of Mdm2 in 
oligodendrogenesis, we demonstrated that, in immature OLs, a pool of endogenous GRK2 
and Mdm2 indeed co-immunoprecipitated in the same molecular complex. More relevant, 
inhibition of mTOR by RAPA markedly increased GRK2/Mdm2 association. Moreover, 
likely due to Mdm2 increased availability, disruption of the p53-Mdm2 complex by Nutlin-3 
potentiated GRK2/Mdm2 association, sequentially leading to (i) decreased GRK2 levels, (ii) 
reduced GRK2-GPR17 interaction after LTD4 stimulation, (iii) inhibition of LTD4-induced 
GPR17 desensitization and, (iv) impaired OPC maturation. These effects were specific for 
LTD4, since Nutlin-3 did not affect UDP-glucose-induced GPR17 desensitization. Based on 
these data, we speculate that, similarly to other disorders (i.e., rheumatoid arthritis (Lombardi 
et al., 1999; Taranto et al., 2005), low levels of GRK2 under demyelinating conditions may 
be due to a primary functional change of Mdm2, thus unveiling this ligase as a new player in 
OPCs terminal differentiation.  
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Figure legends 
 
Figure 1. mTOR inhibition by rapamycin impairs OPC maturation and increases 
GPR17 protein levels. (A) The scheme shows the experimental protocol of RAPA treatment 
and the different stages of OPC differentiation, starting from early oligodendrocyte 
precursors (stage 1) to mature OLs (stage 5). RAPA treatment was started at day 1 and 
differentiation media with or without RAPA was replenished every 72h. In most cases, 
analysis was performed at stage 4 and 5 (red circles); the outcome of these experiments is 
shown in the text. (B) Primary purified OPCs were cultured in the presence of PDGF and of 
bFGF for two days. Cell differentiation was induced by adding T3 to the medium. RAPA (15 
nM) was added at day 1 and day 4. At day 6 (mature OLs, stage 5), cells were fixed for ICC 
analysis or lysed for WB analysis. Representative images of CTRL and RAPA treated-cells, 
showing double immunostaining with anti-GPR17 (green) and anti-MBP (red) antibodies. 
Histograms show the quantification of the percentage of GPR17 and MBP positive cells in 
control and treated cells (with vehicle-treated control cells set to 100%). Hoechst 33258 was 
used to label cell nuclei. The number of positive cells was counted in 10 optical fields under a 
20X magnification. Data are the mean ± S.E. of cell counts from a total of 3 
coverslips/condition from three independent experiments, **p <0.01; ***p <0.001 compared 
to CTRL, Student t-test. (C) Representative immunoblots of GPR17, CNPase and MBP 
protein levels in CTRL and RAPA treated-cells. Histograms show the results of densitometric 
analysis. Scanning densitometry was quantified and normalized to control (set to 100%) on 
the same WB. α-tubulin expression was analysed from the same samples as an internal 
control. Data are expressed as mean ± S.E. of three independent experiments. *p <0.05; **p 
<0.01; compared to CTRL, non parametric Mann-Whitney test. (D) Primary OPCs were 
transfected with a GPR17-EGFP fusion vector for GPR17 over-expression or with the control 
plasmid (containing EGFP only). After 48/72h, cells were fixed and stained for CNPase 
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(red). Scale bar 20µm. The percentage of transfected cells expressing CNPase over the total 
transfected cell population in the two conditions analysed was shown in the histogram. 
Forced GPR17 over-expression throughout differentiation stages significantly impairs 
spontaneous cell maturation ***p <0.001 compared to control, Student’s t-test, from 4 
independent experiments. 
 
Figure 2. GRK2 plays a key role in mTOR regulation of GPR17 function and OL 
maturation. (A) Representative immunoblots of GRK2 protein levels in CTRL and in RAPA 
treated cells. Histograms show the result of densitometric analysis. Scanning densitometry 
was quantified and normalized to control (set to 100%) on the same WB. α-tubulin 
expression was analysed from the same samples as an internal control. Data from two 
independent experiments were shown (mean ± S.E., *p <0.05 compared to CTRL, non 
parametric Mann-Whitney test). (B) Primary OPCs were treated with medium alone (basal), 
5 µM UDP-glucose, or 50 nM LTD4, in the absence (CTRL) or in the presence of 15 nM 
RAPA. Cell lysates (30 µg) were captured on wells pre-coated with anti-GPR17 antibody. 
After extensive washes, levels of GPR17/GRK2 complexes were quantified using a specific 
anti-GRK2 antibody. Data are the mean ± S.E. of two independent experiments. One-way 
ANOVA followed by Bonferroni post-test: *p < 0.05, ***p <0.001 vs. basal value. (C) 
OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 nM 
LTD4 for different times (5-120 min), in the absence (white bars, CTRL) or in the presence 
(black bars) of 15 nM RAPA. After extensive washing, cells were treated for 15 min with 10 
µM FK, in the absence or in the presence of 5 nM LTD4. Intracellular cAMP levels were 
evaluated as reported in Materials and Methods. Data are expressed as the percentage of FK-
stimulated cAMP levels, set to 100%, and represent the mean ± S.E. of three independent 
experiments: *p <0.05, ***p <0.001 vs LTD4 stimuli, #p <0.05, ###p <0.001 vs relative 
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control cells, one-way ANOVA followed by Bonferroni post-test. (D) OPCs were 
electroporated with a GRK2 encoding plasmid. GRK2 over-expression was verified by WB 
(see the representative immunoblots). 30 h after transfection, cells were treated with 50 nM 
LTD4 for different times (30-120 min), in the absence (white bars, CTRL) or presence of 15 
nM RAPA (black bars). After extensive washing, cells were treated for 15 min with 10 µM 
FK, in the absence or in the presence of 5 nM LTD4 and intracellular cAMP levels were 
evaluated. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, 
and represent the mean ± S.E. of two independent experiments. *p <0.05, **p <0.01, ***p 
<0.001 vs LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test.  
 
Figure 3. The ubiquitin ligase Mdm2 mediates the interaction between GRK2 and 
mTOR. Primary OPCs were pre-incubated for 15 min with 15 nM RAPA (A) or 10 µM NUT 
(B) and treated with medium alone (basal), or UDP-glucose (5 µM) or with LTD4 (50 nM), 
respectively for 30 min. Cell lysates (30 µg) were captured on wells pre-coated with anti-
Mdm2 antibody. After extensive washes, levels of Mdm2/GRK complexes were quantified 
using specific anti-GRK2 or anti-GRK5 antibodies, and subsequently an HRP-conjugated 
antibody/TMB substrate kit. Blank wells were obtained in the absence of the primary anti-
GRK antibodies. Data are expressed as fold vs. basal, and represent the mean ± S.E. of at 
least three independent experiments. **p < 0.01; ***p < 0.001 vs. basal value, one-way 
ANOVA with Bonferroni post-test. (C) Primary OPCs (stage 3) were treated with medium 
alone (CTRL) or 15 nM RAPA for 30 min. At the end of the treatment period, cytosolic and 
nuclear fractions were collected. Representative immunoblots of Mdm2 levels in CTRL and 
in RAPA-treated cells. Histograms show the result of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-
actin and hystone H3 expression were analysed from the same samples as loading controls 
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for the cytosolic and nuclear fraction, respectively. Data are expressed as mean ± S.E. of two 
independent experiments. One-way ANOVA followed by Bonferroni post-test: ***p <0.001 
compared to CTRL. (D) Representative immunoblots of GRK2 and GPR17 and CNPase 
protein levels in CTRL and in Nutlin-3 (NUT) treated cells. Histograms show the result of 
densitometric analysis. Scanning densitometry was quantified and normalized to control (set 
to 100%) on the same WB. α-tubulin expression was analysed from the same samples as an 
internal control. Data are expressed as mean ± S.E. of two independent experiments, *p <0.05 
compared to CTRL, non parametric Mann-Whitney test. (E) Primary OPCs were treated with 
medium alone (basal), 5 µM UDP-glucose, or 50 nM LTD4, in the absence (control) or in the 
presence of 10 µM NUT. Cell lysates (30 µg) were captured on wells pre-coated with anti-
GPR17 antibody. After extensive washes, levels of GPR17/GRK complexes were quantified 
using a specific anti-GRK2 antibody. Data are the mean ± S.E. of two independent 
experiments. Statistical significance was determined with a one-way ANOVA with 
Bonferroni post-test: *p < 0.05, ***p < 0.001 vs. basal value; #p < 0.05, ##p <0.01, ###p 
<0.001 vs. respective CTRL.  
 
Figure 4. Sequestration of GRK2 by Mdm2 prevents GPR17 desensitization and OL 
maturation. (A) OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were 
treated with 50 nM LTD4 or 5 µM UDP-glucose (B) for different times (5-120 min), in the 
absence (white bars, CTRL) or presence of 10 µM NUT (black bars). After extensive 
washing, cells were treated for 15 min with 10 µM FK, in the absence or in the presence of 
500 nM UDP-glucose or 5 nM LTD4 and intracellular cAMP levels were evaluated. Data are 
expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the 
mean ± S.E. of three independent experiments. *p <0.05, **p <0.01, ***p <0.001 vs UDP-
glucose or LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test. (C) Primary 
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purified OPCs were cultured in the presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 to the medium. NUT (1 µM) was added at day 1, 30 
minutes before treating cells with LTD4 (100 nM) or with vehicle. The differentiation degree 
of cells was monitored by analysing the number of cells expressing MBP at stage 4. 
Representative images of control (CTRL), NUT, LTD4 and NUT+LTD4 showing 
immunostaining with anti-MBP antibody (red). Histograms show the quantification of the 
percentage of MBP
+ 
cells in control and treated cells (with vehicle-treated control cells set to 
100%). Hoechst 33258 was used to label cell nuclei. The number of MBP
+
-cells was counted 
in the entire coverslip under a 40X magnification. Data are the mean ± S.E. of cell counts 
from a total of 3 coverslips/condition from three independent experiments *p <0.05; **p 
<0.01 compared to CTRL, ##p <0.01 compared to LTD4, non parametric Mann-Whitney test. 
 
Figure 5. Postnatal in vivo mTOR inhibition with rapamycin alters the normal 
development of GPR17, GRK2 and myelin associated proteins. (A) The drawing shows 
the experimental plan for the in vivo treatment. C57BL6/J mice were injected daily with 
either vehicle (3 animals) or rapamycin (3 animals) intraperitoneally at a dose of 10 mg/kg 
body weight, starting from postnatal day (P) 16 to P20. On P21, mice were sacrificed, brains 
extracted, rapidly frozen at -80°C and processed for western-blot analysis. (B) Representative 
immunoblots of phospho-mTOR, mTOR, GPR17, GRK2, CNPase and MBP protein levels in 
control (CTRL) and rapamycin (RAPA) treated mice. Histograms show the result of 
densitometric analysis. Scanning densitometry was quantified and normalized to control 
condition (set to 100%) on the same western blot membrane. α-tubulin expression was 
analysed from the same samples as an internal control. Data are expressed as mean ± S.E. * p 
<0.05; compared to CTRL, non parametric Mann-Whitney test. 
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Figure 6. A cartoon illustrating the signalling pathways involved in GPR17 
desensitization/down-regulation and OPC maturation. (A) Under conditions leading to 
physiological activation of the mTOR pathway, Mdm2 is mainly associated to the nucleus 
and bound to p53 and does not interfere with GRK2-mediated GPR17 desensitization in 
response to LTD4. (B) Inhibition of mTOR by rapamycin induced a redistribution of the 
intracellular concentrations of Mdm2, reducing its nuclear interaction with p53 and 
increasing the Mdm2/GRK2 association, causing a reduction of the expression levels of 
GRK2 and a subsequent loss in GPR17 desensitization in response to LTD4. The latter event 
impairs OPC maturation. To confirm the role of Mdm2 in GPR17 desensitization, Nutlin-3, 
releasing Mdm2 from its complex with p53, favoured the degradation of GRK2 and thus 
impairing GPR17 desensitization and OPC maturation. 
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Figure 1. mTOR inhibition by rapamycin impairs OPC maturation and increases GPR17 protein levels. (A) The 
scheme shows the experimental protocol of RAPA treatment and the different stages of OPC differentiation, 
starting from early oligodendrocyte precursors (stage 1) to mature OLs (stage 5). RAPA treatment was 
started at day 1 and differentiation media with or without RAPA was replenished every 72h. In most cases, 
analysis was performed at stage 4 and 5 (red circles); the outcome of these experiments is shown in the 
text. (B) Primary purified OPCs were cultured in the presence of PDGF and of bFGF for two days. Cell 
differentiation was induced by adding T3 to the medium. RAPA (15 nM) was added at day 1 and day 4. At 
day 6 (mature OLs, stage 5), cells were fixed for ICC analysis or lysed for WB analysis. Representative 
images of CTRL and RAPA treated-cells, showing double immunostaining with anti-GPR17 (green) and anti-
MBP (red) antibodies. Histograms show the quantification of the percentage of GPR17 and MBP positive cells 
in control and treated cells (with vehicle-treated control cells set to 100%). Hoechst 33258 was used to label 
cell nuclei. The number of positive cells was counted in 10 optical fields under a 20X magnification. Data are 
the mean ± S.E. of cell counts from a total of 3 coverslips/condition from three independent experiments, 
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**p <0.01; ***p <0.001 compared to CTRL, Student t-test. (C) Representative immunoblots of GPR17, 
CNPase and MBP protein levels in CTRL and RAPA treated-cells. Histograms show the results of 
densitometric analysis. Scanning densitometry was quantified and normalized to control (set to 100%) on 
the same WB. α-tubulin expression was analysed from the same samples as an internal control. Data are 
expressed as mean ± S.E. of three independent experiments. *p <0.05; **p <0.01; compared to CTRL, non 
parametric Mann-Whitney test. (D) Primary OPCs were transfected with a GPR17-EGFP fusion vector for 
GPR17 over-expression or with the control plasmid (containing EGFP only). After 48/72h, cells were fixed 
and stained for CNPase (red). Scale bar 20µm. The percentage of transfected cells expressing CNPase over 
the total transfected cell population in the two conditions analysed was shown in the histogram. Forced 
GPR17 over-expression throughout differentiation stages significantly impairs spontaneous cell maturation 
***p <0.001 compared to control, Student’s t-test, from 4 independent experiments.  
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Figure 2. GRK2 plays a key role in mTOR regulation of GPR17 function and OL maturation. (A) 
Representative immunoblots of GRK2 protein levels in CTRL and in RAPA treated cells. Histograms show the 
result of densitometric analysis. Scanning densitometry was quantified and normalized to control (set to 
100%) on the same WB. α-tubulin expression was analysed from the same samples as an internal control. 
Data from two independent experiments were shown (mean ± S.E., *p <0.05 compared to CTRL, non 
parametric Mann-Whitney test). (B) Primary OPCs were treated with medium alone (basal), 5 µM UDP-
glucose, or 50 nM LTD4, in the absence (CTRL) or in the presence of 15 nM RAPA. Cell lysates (30 µg) were 
captured on wells pre-coated with anti-GPR17 antibody. After extensive washes, levels of GPR17/GRK2 
complexes were quantified using a specific anti-GRK2 antibody. Data are the mean ± S.E. of two 
independent experiments. One-way ANOVA followed by Bonferroni post-test: *p < 0.05, ***p <0.001 vs. 
basal value. (C) OPCs, isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 
nM LTD4 for different times (5-120 min), in the absence (white bars, CTRL) or in the presence (black bars) 
of 15 nM RAPA. After extensive washing, cells were treated for 15 min with 10 µM FK, in the absence or in 
the presence of 5 nM LTD4. Intracellular cAMP levels were evaluated as reported in Materials and Methods. 
Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the mean ± 
S.E. of three independent experiments: *p <0.05, ***p <0.001 vs LTD4 stimuli, #p <0.05, ###p <0.001 
vs relative control cells, one-way ANOVA followed by Bonferroni post-test. (D) OPCs were electroporated 
with a GRK2 encoding plasmid. GRK2 over-expression was verified by WB (see the representative 
immunoblots). 30 h after transfection, cells were treated with 50 nM LTD4 for different times (30-120 min), 
in the absence (white bars, CTRL) or presence of 15 nM RAPA (black bars). After extensive washing, cells 
were treated for 15 min with 10 µM FK, in the absence or in the presence of 5 nM LTD4 and intracellular 
cAMP levels were evaluated. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 
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100%, and represent the mean ± S.E. of two independent experiments. *p <0.05, **p <0.01, ***p <0.001 
vs LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test.  
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Figure 3. The ubiquitin ligase Mdm2 mediates the interaction between GRK2 and mTOR. Primary OPCs were 
pre-incubated for 15 min with 15 nM RAPA (A) or 10 µM NUT (B) and treated with medium alone (basal), or 
UDP-glucose (5 µM) or with LTD4 (50 nM), respectively for 30 min. Cell lysates (30 µg) were captured on 
wells pre-coated with anti-Mdm2 antibody. After extensive washes, levels of Mdm2/GRK complexes were 
quantified using specific anti-GRK2 or anti-GRK5 antibodies, and subsequently an HRP-conjugated 
antibody/TMB substrate kit. Blank wells were obtained in the absence of the primary anti-GRK antibodies. 
Data are expressed as fold vs. basal, and represent the mean ± S.E. of at least three independent 
experiments. **p < 0.01; ***p < 0.001 vs. basal value, one-way ANOVA with Bonferroni post-test. (C) 
Primary OPCs (stage 3) were treated with medium alone (CTRL) or 15 nM RAPA for 30 min. At the end of 
the treatment period, cytosolic and nuclear fractions were collected. Representative immunoblots of Mdm2 
levels in CTRL and in RAPA-treated cells. Histograms show the result of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-actin and hystone 
H3 expression were analysed from the same samples as loading controls for the cytosolic and nuclear 
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fraction, respectively. Data are expressed as mean ± S.E. of two independent experiments. One-way ANOVA 
followed by Bonferroni post-test: ***p <0.001 compared to CTRL. (D) Representative immunoblots of GRK2 
and GPR17 and CNPase protein levels in CTRL and in Nutlin-3 (NUT) treated cells. Histograms show the 
result of densitometric analysis. Scanning densitometry was quantified and normalized to control (set to 
100%) on the same WB. α-tubulin expression was analysed from the same samples as an internal control. 
Data are expressed as mean ± S.E. of two independent experiments, *p <0.05 compared to CTRL, non 
parametric Mann-Whitney test. (E) Primary OPCs were treated with medium alone (basal), 5 µM UDP-
glucose, or 50 nM LTD4, in the absence (control) or in the presence of 10 µM NUT. Cell lysates (30 µg) were 
captured on wells pre-coated with anti-GPR17 antibody. After extensive washes, levels of GPR17/GRK 
complexes were quantified using a specific anti-GRK2 antibody. Data are the mean ± S.E. of two 
independent experiments. Statistical significance was determined with a one-way ANOVA with Bonferroni 
post-test: *p < 0.05, ***p < 0.001 vs. basal value; #p < 0.05, ##p <0.01, ###p <0.001 vs. respective 
CTRL.  
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Figure 4. Sequestration of GRK2 by Mdm2 prevents GPR17 desensitization and OL maturation. (A) OPCs, 
isolated and differentiated at pre-oligodendrocytes (stage 3), were treated with 50 nM LTD4 or 5 µM UDP-
glucose (B) for different times (5-120 min), in the absence (white bars, CTRL) or presence of 10 µM NUT 
(black bars). After extensive washing, cells were treated for 15 min with 10 µM FK, in the absence or in the 
presence of 500 nM UDP-glucose or 5 nM LTD4 and intracellular cAMP levels were evaluated. Data are 
expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the mean ± S.E. of 
three independent experiments. *p <0.05, **p <0.01, ***p <0.001 vs UDP-glucose or LTD4 stimuli, one-
way ANOVA followed by Bonferroni post-test. (C) Primary purified OPCs were cultured in the presence of 
PDGF and of bFGF for two days. Cell differentiation was induced by adding T3 to the medium. NUT (1 µM) 
was added at day 1, 30 minutes before treating cells with LTD4 (100 nM) or with vehicle. The differentiation 
degree of cells was monitored by analysing the number of cells expressing MBP at stage 4. Representative 
images of control (CTRL), NUT, LTD4 and NUT+LTD4 showing immunostaining with anti-MBP antibody (red). 
Histograms show the quantification of the percentage of MBP+ cells in control and treated cells (with 
vehicle-treated control cells set to 100%). Hoechst 33258 was used to label cell nuclei. The number of 
MBP+-cells was counted in the entire coverslip under a 40X magnification. Data are the mean ± S.E. of cell 
counts from a total of 3 coverslips/condition from three independent experiments *p <0.05; **p <0.01 
compared to CTRL, ##p <0.01 compared to LTD4, non parametric Mann-Whitney test.  
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Figure 5. Postnatal in vivo mTOR inhibition with rapamycin alters the normal development of GPR17, GRK2 
and myelin associated proteins. (A) The drawing shows the experimental plan for the in vivo treatment. 
C57BL6/J mice were injected daily with either vehicle (3 animals) or rapamycin (3 animals) intraperitoneally 
at a dose of 10 mg/kg body weight, starting from postnatal day (P) 16 to P20. On P21, mice were sacrificed, 
brains extracted, rapidly frozen at -80°C and processed for western-blot analysis. (B) Representative 
immunoblots of phospho-mTOR, mTOR, GPR17, GRK2, CNPase and MBP protein levels in control (CTRL) and 
rapamycin (RAPA) treated mice. Histograms show the result of densitometric analysis. Scanning 
densitometry was quantified and normalized to control condition (set to 100%) on the same western blot 
membrane. α-tubulin expression was analysed from the same samples as an internal control. Data are 
expressed as mean ± S.E. * p <0.05; compared to CTRL, non parametric Mann-Whitney test.  
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Figure 6. A cartoon illustrating the signalling pathways involved in GPR17 desensitization/down-regulation 
and OPC maturation. (A) Under conditions leading to physiological activation of the mTOR pathway, Mdm2 is 
mainly associated to the nucleus and bound to p53 and does not interfere with GRK2-mediated GPR17 
desensitization in response to LTD4. (B) Inhibition of mTOR by rapamycin induced a redistribution of the 
intracellular concentrations of Mdm2, reducing its nuclear interaction with p53 and increasing the 
Mdm2/GRK2 association, causing a reduction of the expression levels of GRK2 and a subsequent loss in 
GPR17 desensitization in response to LTD4. The latter event impairs OPC maturation. To confirm the role of 
Mdm2 in GPR17 desensitization, Nutlin-3, releasing Mdm2 from its complex with p53, favoured the 
degradation of GRK2 and thus impairing GPR17 desensitization and OPC maturation.  
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Supplementary materials and methods 
 
Myelinating co-cultures. DRG-OPC co-cultures were prepared according to a previously 
described protocol (Taveggia et al., 2008). Briefly, DRG from E14.5 mouse embryos were 
plucked off from spinal cord, put in culture (1 DRG/coverslip) in Neurobasal supplemented 
with B27 in the presence of NGF (100 ng/ml) (Harlan, Milan, Italy) and cycled with 10 µM 
fluorodeoxyuridine, Sigma Aldrich) to eliminate all non-neuronal cells. After 20 days, when 
neurites were well extended radially from DRG explants, 35,000 OPCs were added to each 
DRG in culture and kept in MEM (Life Technologies) supplemented with glucose (4 g/L) 
(Sigma Aldrich), 10% FBS and 2 mM L-glutamine. Myelination was induced the following 
day by the addition of recombinant chimeric TrkA-Fc (1 µg/ml) (Space Import Export) to the 
culture medium.  
 
Co-immunoprecipitation Assay. Primary OPCs (stage 3) were treated with medium alone 
(CTRL), 15 nM RAPA or 10 µM Nutlin-3 for 30 min, and then lysed for 60 min at 4 °C by 
the addition of RIPA buffer (9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl, pH 7.4, 
0.5% sodium deoxycholate, 1% Nonidet P-40, and 0.1% SDS, protease inhibitor cocktail). 
Extracts were then equalised by protein assay. Mdm2 immunoprecipitates were obtained as 
described previously (Costa et al., 2013). Briefly, 500 µg cell lysates were incubated with 
anti-Mdm2 (Santa Cruz Biotechnology, sc-812; 5 µg/sample) overnight at 4 °C under 
constant rotation. Probes were then immunoprecipitated with protein A-Sepharose (2–3 h at 4 
°C). Immunocomplexes, after being washed, were resuspended in Laemmli solution and 
boiled for 5 min, resolved by SDS-PAGE (8.5%), transferred to PVDF membranes and 
probed overnight at 4 °C with the specific primary antibodies anti-GRK2 (Santa Cruz 
Biotechnology, Dallas, TX, USA, sc-562; 1:200) or anti-Mdm2.  
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In vivo rapamycin injections. C57BL6/J mice were injected daily with either vehicle or 
rapamycin intraperitoneally at 10 mg/kg body weight (rapamycin was diluted in the vehicle 
solution from a stock of 20 mg/mL in 100% ethanol immediately before the injection to a 
final concentration of 0.8 mg/mL PBS, 5% polyethylene glycol-1000, 5% Tween 80, and 4% 
ethanol) starting at postnatal day (P) 16. On P21, mice were sacrificed, brains were extracted 
and rapidly frozen at -80°C. Membrane protein extracts were obtained by tissue 
homogenization in lysis buffer (20 mM Tris pH 7.2, 0.5% deoxycholate, 1% Triton, 0.1% 
SDS, 150 mM NaCl, 1 mM EDTA and 1% proteases inhibitors, Sigma-Aldrich). The 
homogenate was centrifuged at 1000g for 10 min at 4°C in order to eliminate nuclei. The 
protein concentration was estimated using the Bio-Rad Protein Assay (Bio-Rad Laboratories 
s.r.l., Segrate, Italy). Western blot analysis was performed as described in the section of 
Materials and methods.  
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Supplementary Figure Legends 
 
Figure S1. Involvement of mTOR in GPR17 regulation during OPC maturation. (A) 
Primary purified OPCs were cultured in the presence of PDGF and of bFGF for two days. 
Cell differentiation was induced by adding T3 to the medium. RAPA (15 nM) was added at 
day 1 and day 4. At day 4 (immature OLs, stage 4), cells were lysed for western-blot analysis. 
Representative immunoblots of GPR17, CNPase and MBP protein levels in CTRL and 
RAPA treated-cells. Histograms show the results of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-
tubulin expression was analysed from the same samples as an internal control. Data are 
expressed as mean ± S.E. of three independent experiments. *p<0.05; compared to CTRL, 
non parametric Mann-Whitney test. (B) OPC/DRG co-cultures were exposed for 10 days to 
RAPA (15 nM) or vehicle. Representative images of CTRL and RAPA-treated cells show 
double immunostaining for anti-MBP antibody (red) and anti-neurofilament Smi31 and 
Smi32 antibodies (indicated as NF, green), scale bar: 20 µm. 
 
Figure S2. OPCs electroporation with a control vector does not affect GPR17 
desensitization. OPCs were transfected by electroporation with the same empty vector 
utilized for GRK2 transfection (see Fig. 2D). After 30 h, cells were treated with 50 nM LTD4 
for different times (30-120 min), in the absence (white bars, CTRL) or presence of 15 nM 
RAPA (black bars). After extensive washing, cells were treated for 15 min with 10 µM FK, 
in the absence or in the presence of 5 nM LTD4 and intracellular cAMP levels were 
evaluated. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, 
and represent the mean ± S.E. of two independent experiments. *p <0.05, **p <0.01, ***p 
<0.001 vs LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test. 
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Figure S3. GRK5 is not involved in mTOR regulation of GPR17 function and OL 
maturation. (A) Representative immunoblots of GRK5 protein levels in CTRL and in RAPA 
treated cells at stage 4 and stage 5. Histograms show the result of densitometric analysis. 
Scanning densitometry was quantified and normalized to control (set to 100%) on the same 
WB. α-tubulin expression was analysed from the same samples as an internal control. Data 
from two independent experiments were shown. (B) OPCs, isolated and differentiated at pre-
oligodendrocytes (stage 3), were treated with 5 µM UDP-glucose for different times (5-120 
min), in the absence (white bars, CTRL) or in the presence (black bars) of 15 nM RAPA. 
After extensive washing, cells were treated for 15 min with 10 µM FK, in the absence or in 
the presence of 500 nM UDP-glucose. Intracellular cAMP levels were evaluated as reported 
in Materials and Methods. Data are expressed as the percentage of FK-stimulated cAMP 
levels, set to 100%, and represent the mean ± S.E. of three independent experiments: *P 
<0.05, **P<0.01, ***P<0.001 vs UDP-glucose stimuli, one-way ANOVA followed by 
Bonferroni post-test  
 
Figure S3 Postnatal in vivo mTOR inhibition with rapamycin alters the normal 
development of GPR17, GRK2 and myelin associated proteins. (A) The drawing shows 
the experimental plan for the in vivo treatment. C57BL6/J mice were injected daily with 
either vehicle (3 animals) or rapamycin (3 animals) intraperitoneally at a dose of 10 mg/kg 
body weight, starting from postnatal day (P) 16 to P20. On P21, mice were sacrificed, brains 
extracted, rapidly frozen at -80°C and processed for western-blot analysis. (B) Representative 
immunoblots of phospho-mTOR, mTOR, GPR17, GRK2, CNPase and MBP protein levels in 
control (CTRL) and rapamycin (RAPA) treated mice. Histograms show the result of 
densitometric analysis. Scanning densitometry was quantified and normalized to control 
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condition (set to 100%) on the same western blot membrane. α-tubulin expression was 
analysed from the same samples as an internal control.  
 
Figure S4. Both RAPA and NUT markedly reduce the Mmd2-p53 association complex. 
Primary OPCs (stage 3) were treated with either medium alone (basal), or 15 nM RAPA or 
10 µM Nutlin-3 for 30 min. At the end of treatments, OPCs were lysed and then captured on 
wells pre-coated with anti-Mdm2 antibody. After extensive washes, levels of Mdm2/p53 
complexes were quantified using a specific anti-p53 antibody. Data are the mean ± S.E. of 
two independent experiments. One-way ANOVA followed by Bonferroni post-test: **p 
<0.001, ***p <0.001 vs. basal value. 
 
Figure S5. Both RAPA and NUT increase the interaction between Mdm2 and GRK2. 
Primary OPCs (stage 3) were treated with either medium alone (CTRL), or 15 nM RAPA or 
10 µM Nutlin-3 for 30 min. (A) Representative immunoblots of Mdm2-GRK2 
immunocomplex levels in CTRL, RAPA and in NUT treated cells. Histograms show the 
result of densitometric analysis. Scanning densitometry was quantified and normalized to 
control (set to 100%) on the same WB. Mdm2 expression was analysed from the same 
samples as internal control. Data are expressed as mean ± S.E. of two independent 
experiments. One-way ANOVA followed by Bonferroni post-test: **p <0.01, ***p <0.001 
compared to CTRL. 
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Supplementary materials and methods 
 
Myelinating co-cultures. DRG-OPC co-cultures were prepared according to a previously 
described protocol (Taveggia et al., 2008). Briefly, DRG from E14.5 mouse embryos were 
plucked off from spinal cord, put in culture (1 DRG/coverslip) in Neurobasal supplemented 
with B27 in the presence of NGF (100 ng/ml) (Harlan, Milan, Italy) and cycled with 10 µM 
fluorodeoxyuridine, Sigma Aldrich) to eliminate all non-neuronal cells. After 20 days, when 
neurites were well extended radially from DRG explants, 35,000 OPCs were added to each 
DRG in culture and kept in MEM (Life Technologies) supplemented with glucose (4 g/L) 
(Sigma Aldrich), 10% FBS and 2 mM L-glutamine. Myelination was induced the following 
day by the addition of recombinant chimeric TrkA-Fc (1 µg/ml) (Space Import Export) to the 
culture medium.  
 
Co-immunoprecipitation Assay. Primary OPCs (stage 3) were treated with medium alone 
(CTRL), 15 nM RAPA or 10 µM Nutlin-3 for 30 min, and then lysed for 60 min at 4 °C by 
the addition of RIPA buffer (9.1 mM NaH2PO4, 1.7 mM Na2HPO4, 150 mM NaCl, pH 7.4, 
0.5% sodium deoxycholate, 1% Nonidet P-40, and 0.1% SDS, protease inhibitor cocktail). 
Extracts were then equalised by protein assay. Mdm2 immunoprecipitates were obtained as 
described previously (Costa et al., 2013). Briefly, 500 µg cell lysates were incubated with 
anti-Mdm2 (Santa Cruz Biotechnology, sc-812; 5 µg/sample) overnight at 4 °C under 
constant rotation. Probes were then immunoprecipitated with protein A-Sepharose (2–3 h at 4 
°C). Immunocomplexes, after being washed, were resuspended in Laemmli solution and 
boiled for 5 min, resolved by SDS-PAGE (8.5%), transferred to PVDF membranes and 
probed overnight at 4 °C with the specific primary antibodies anti-GRK2 (Santa Cruz 
Biotechnology, Dallas, TX, USA, sc-562; 1:200) or anti-Mdm2.  
Page 79 of 85
John Wiley & Sons, Inc.
GLIA
 3
Supplementary Figure Legends 
 
Figure S1. Involvement of mTOR in GPR17 regulation during OPC maturation. (A) 
Primary purified OPCs were cultured in the presence of PDGF and of bFGF for two days. 
Cell differentiation was induced by adding T3 to the medium. RAPA (15 nM) was added at 
day 1 and day 4. At day 4 (immature OLs, stage 4), cells were lysed for western-blot analysis. 
Representative immunoblots of GPR17, CNPase and MBP protein levels in CTRL and 
RAPA treated-cells. Histograms show the results of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-
tubulin expression was analysed from the same samples as an internal control. Data are 
expressed as mean ± S.E. of three independent experiments. *p<0.05; compared to CTRL, 
non parametric Mann-Whitney test. (B) OPC/DRG co-cultures were exposed for 10 days to 
RAPA (15 nM) or vehicle. Representative images of CTRL and RAPA-treated cells show 
double immunostaining for anti-MBP antibody (red) and anti-neurofilament Smi31 and 
Smi32 antibodies (indicated as NF, green), scale bar: 20 µm. 
 
Figure S2. OPCs electroporation with a control vector does not affect GPR17 
desensitization. OPCs were transfected by electroporation with the same empty vector 
utilized for GRK2 transfection (see Fig. 2D). After 30 h, cells were treated with 50 nM LTD4 
for different times (30-120 min), in the absence (white bars, CTRL) or presence of 15 nM 
RAPA (black bars). After extensive washing, cells were treated for 15 min with 10 µM FK, 
in the absence or in the presence of 5 nM LTD4 and intracellular cAMP levels were 
evaluated. Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, 
and represent the mean ± S.E. of two independent experiments. *p <0.05, **p <0.01, ***p 
<0.001 vs LTD4 stimuli, one-way ANOVA followed by Bonferroni post-test. 
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Figure S3. GRK5 is not involved in mTOR regulation of GPR17 function and OL 
maturation. (A) Representative immunoblots of GRK5 protein levels in CTRL and in RAPA 
treated cells at stage 4 and stage 5. Histograms show the result of densitometric analysis. 
Scanning densitometry was quantified and normalized to control (set to 100%) on the same 
WB. α-tubulin expression was analysed from the same samples as an internal control. Data 
from two independent experiments were shown. (B) OPCs, isolated and differentiated at pre-
oligodendrocytes (stage 3), were treated with 5 µM UDP-glucose for different times (5-120 
min), in the absence (white bars, CTRL) or in the presence (black bars) of 15 nM RAPA. 
After extensive washing, cells were treated for 15 min with 10 µM FK, in the absence or in 
the presence of 500 nM UDP-glucose. Intracellular cAMP levels were evaluated as reported 
in Materials and Methods. Data are expressed as the percentage of FK-stimulated cAMP 
levels, set to 100%, and represent the mean ± S.E. of three independent experiments: *P 
<0.05, **P<0.01, ***P<0.001 vs UDP-glucose stimuli, one-way ANOVA followed by 
Bonferroni post-test  
 
Figure S4. Both RAPA and NUT markedly reduce the Mmd2-p53 association complex. 
Primary OPCs (stage 3) were treated with either medium alone (basal), or 15 nM RAPA or 
10 µM Nutlin-3 for 30 min. At the end of treatments, OPCs were lysed and then captured on 
wells pre-coated with anti-Mdm2 antibody. After extensive washes, levels of Mdm2/p53 
complexes were quantified using a specific anti-p53 antibody. Data are the mean ± S.E. of 
two independent experiments. One-way ANOVA followed by Bonferroni post-test: **p 
<0.001, ***p <0.001 vs. basal value. 
 
Figure S5. Both RAPA and NUT increase the interaction between Mdm2 and GRK2. 
Primary OPCs (stage 3) were treated with either medium alone (CTRL), or 15 nM RAPA or 
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10 µM Nutlin-3 for 30 min. (A) Representative immunoblots of Mdm2-GRK2 
immunocomplex levels in CTRL, RAPA and in NUT treated cells. Histograms show the 
result of densitometric analysis. Scanning densitometry was quantified and normalized to 
control (set to 100%) on the same WB. Mdm2 expression was analysed from the same 
samples as internal control. Data are expressed as mean ± S.E. of two independent 
experiments. One-way ANOVA followed by Bonferroni post-test: **p <0.01, ***p <0.001 
compared to CTRL. 
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Figure S1. Involvement of mTOR in GPR17 regulation during OPC maturation. (A) Primary purified OPCs 
were cultured in the presence of PDGF and of bFGF for two days. Cell differentiation was induced by adding 
T3 to the medium. RAPA (15 nM) was added at day 1 and day 4. At day 4 (immature OLs, stage 4), cells 
were lysed for western-blot analysis. Representative immunoblots of GPR17, CNPase and MBP protein levels 
in CTRL and RAPA treated-cells. Histograms show the results of densitometric analysis. Scanning 
densitometry was quantified and normalized to control (set to 100%) on the same WB. α-tubulin expression 
was analysed from the same samples as an internal control. Data are expressed as mean ± S.E. of three 
independent experiments. *p<0.05; compared to CTRL, non parametric Mann-Whitney test. (B) OPC/DRG 
co-cultures were exposed for 10 days to RAPA (15 nM) or vehicle. Representative images of CTRL and RAPA-
treated cells show double immunostaining for anti-MBP antibody (red) and anti-neurofilament Smi31 and 
Smi32 antibodies (indicated as NF, green), scale bar: 20 µm.  
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Figure S2. OPCs electroporation with a control vector does not affect GPR17 desensitization. OPCs were 
transfected by electroporation with the same empty vector utilized for GRK2 transfection (see Fig. 2D). After 
30 h, cells were treated with 50 nM LTD4 for different times (30-120 min), in the absence (white bars, 
CTRL) or presence of 15 nM RAPA (black bars). After extensive washing, cells were treated for 15 min with 
10 µM FK, in the absence or in the presence of 5 nM LTD4 and intracellular cAMP levels were evaluated. 
Data are expressed as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the mean ± 
S.E. of two independent experiments. *p <0.05, **p <0.01, ***p <0.001 vs LTD4 stimuli, one-way ANOVA 
followed by Bonferroni post-test.  
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Figure S3. GRK5 is not involved in mTOR regulation of GPR17 function and OL maturation. (A) 
Representative immunoblots of GRK5 protein levels in CTRL and in RAPA treated cells at stage 4 and stage 
5. Histograms show the result of densitometric analysis. Scanning densitometry was quantified and 
normalized to control (set to 100%) on the same WB. α-tubulin expression was analysed from the same 
samples as an internal control. Data from two independent experiments were shown. (B) OPCs, isolated and 
differentiated at pre-oligodendrocytes (stage 3), were treated with 5 µM UDP-glucose for different times (5-
120 min), in the absence (white bars, CTRL) or in the presence (black bars) of 15 nM RAPA. After extensive 
washing, cells were treated for 15 min with 10 µM FK, in the absence or in the presence of 500 nM UDP-
glucose. Intracellular cAMP levels were evaluated as reported in Materials and Methods. Data are expressed 
as the percentage of FK-stimulated cAMP levels, set to 100%, and represent the mean ± S.E. of three 
independent experiments: *P <0.05, **P<0.01, ***P<0.001 vs UDP-glucose stimuli, one-way ANOVA 
followed by Bonferroni post-test.  
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Figure S4. Both RAPA and NUT markedly reduce the Mmd2-p53 association complex. Primary OPCs (stage 3) 
were treated with either medium alone (basal), or 15 nM RAPA or 10 µM Nutlin-3 for 30 min. At the end of 
treatments, OPCs were lysed and then captured on wells pre-coated with anti-Mdm2 antibody. After 
extensive washes, levels of Mdm2/p53 complexes were quantified using a specific anti-p53 antibody. Data 
are the mean ± S.E. of two independent experiments. One-way ANOVA followed by Bonferroni post-test: 
**p <0.001, ***p <0.001 vs. basal value.  
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Figure S5. Both RAPA and NUT increase the interaction between Mdm2 and GRK2. Primary OPCs (stage 3) 
were treated with either medium alone (CTRL), or 15 nM RAPA or 10 µM Nutlin-3 for 30 min. (A) 
Representative immunoblots of Mdm2-GRK2 immunocomplex levels in CTRL, RAPA and in NUT treated cells. 
Histograms show the result of densitometric analysis. Scanning densitometry was quantified and normalized 
to control (set to 100%) on the same WB. Mdm2 expression was analysed from the same samples as 
internal control. Data are expressed as mean ± S.E. of two independent experiments. One-way ANOVA 
followed by Bonferroni post-test: **p <0.01, ***p <0.001 compared to CTRL.  
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